BackgroundUsing	O
antibodies	O
to	O
specific	O
protein	O
antigens	O
is	O
the	O
method	O
of	O
choice	O
to	O
assign	O
and	O
identify	O
cell	O
lineage	O
through	O
simultaneous	O
analysis	O
of	O
surface	O
molecules	O
and	O
intracellular	O
markers	O
.	O

Embryonic	O
stem	O
cell	O
research	O
can	O
be	O
benefited	O
from	O
using	O
antibodies	O
specific	O
to	O
transcriptional	O
factors	O
/	O
markers	O
that	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
or	O
critical	O
for	O
cell	O
lineage	O
.	O

ResultsIn	O
this	O
report	O
,	O
we	O
have	O
developed	O
and	O
validated	O
antibodies	O
(	O
either	O
monoclonal	O
or	O
polyclonal	O
)	O
specific	O
to	O
human	O
embryonic	O
stem	O
cell	O
antigens	O
and	O
early	O
differentiation	O
transcriptional	O
factors	O
/	O
markers	O
that	O
are	O
critical	O
for	O
cell	O
differentiation	O
into	O
definite	O
lineage	O
.	O

ConclusionThese	O
antibodies	O
enable	O
stem	O
cell	O
biologists	O
to	O
conveniently	O
identify	O
stem	O
cell	O
characteristics	O
and	O
to	O
quantitatively	O
assess	O
differentiation	O
.	O

Although	O
the	O
stem	O
cell	O
concept	O
was	O
introduced	O
decades	O
ago	O
,	O
to	O
date	O
,	O
stem	O
cells	O
can	O
only	O
be	O
defined	O
functionally	O
,	O
not	O
morphologically	O
or	O
phenotypically	O
.	O

Two	O
functions	O
define	O
stem	O
cells	O
.	O

Firstly	O
,	O
they	O
are	O
self	O
-	O
renewing	O
,	O
thus	O
able	O
to	O
propagate	O
to	O
generate	O
additional	O
stem	O
cells	O
.	O

Secondly	O
they	O
can	O
differentiate	O
into	O
various	O
progenitor	O
cells	O
,	O
which	O
commit	O
to	O
further	O
maturation	O
along	O
a	O
specific	O
lineage	O
.	O

While	O
stem	O
cells	O
can	O
be	O
best	O
defined	O
functionally	O
,	O
a	O
good	O
number	O
of	O
molecular	O
markers	O
have	O
been	O
used	O
to	O
prospectively	O
identify	O
various	O
stem	O
cell	O
populations	O
.	O

Although	O
the	O
functional	O
importance	O
of	O
many	O
of	O
these	O
antigens	O
remains	O
unknown	O
,	O
their	O
unique	O
expression	O
pattern	O
and	O
timing	O
of	O
expression	O
provide	O
a	O
useful	O
tool	O
for	O
scientists	O
to	O
identify	O
as	O
well	O
as	O
isolate	O
stem	O
cells	O
.	O

Embryonic	O
stem	O
cells	O
(	O
ESC	O
)	O
,	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
pre	O
-	O
implantation	O
embryos	O
,	O
have	O
been	O
recognized	O
as	O
the	O
earliest	O
stem	O
cell	O
population	O
[	O
1,2	O
]	O
.	O

This	O
pluripotent	O
population	O
can	O
differentiate	O
into	O
all	O
somatic	O
tissue	O
including	O
germ	O
cells	O
.	O

In	O
the	O
case	O
of	O
human	O
ESC	O
,	O
they	O
can	O
differentiate	O
into	O
some	O
extra	O
-	O
embryonic	O
derivatives	O
as	O
well	O
.	O

Like	O
mouse	O
ESC	O
,	O
human	O
ES	O
cells	O
can	O
be	O
maintained	O
and	O
propagated	O
on	O
mouse	O
fibroblast	O
feeders	O
for	O
extended	O
periods	O
in	O
media	O
containing	O
basic	B
fibroblast	I
growth	I
factor	I
(	O
bFGF	B
)	O
[	O
3	O
]	O
.	O

Gene	O
expression	O
of	O
undifferentiated	O
human	O
ES	O
cells	O
has	O
been	O
investigated	O
among	O
several	O
ES	O
cell	O
lines	O
by	O
a	O
variety	O
of	O
techniques	O
.	O

They	O
include	O
comparison	O
with	O
databases	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
,	O
focused	O
cDNA	O
microarrays	O
,	O
and	O
immunocytochemistry	O
.	O

A	O
list	O
of	O
molecules	O
comprised	O
of	O
known	O
ES	O
-	O
specific	O
or	O
-highly	O
expressed	O
genes	O
and	O
candidates	O
that	O
can	O
serve	O
as	O
markers	O
for	O
human	O
ESCs	O
and	O
may	O
also	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
has	O
been	O
established	O
[	O
3	O
-	O
11	O
]	O
.	O

For	O
example	O
,	O
pluripotent	O
ESC	O
can	O
be	O
characterized	O
by	O
high	O
level	O
expression	O
of	O
Oct3	B
/	I
4	I
(	O
POU	B
domain	I
,	I
class	I
5	I
,	I
transcription	I
factor	I
1	I
,	O
Pou5f1	B
)	O
and	O
Nanog	B
,	O
which	O
are	O
a	O
member	O
of	O
POU	O
domain	O
and	O
homeobox	O
transcription	O
factors	O
respectively	O
.	O

A	O
critical	O
amount	O
of	O
Oct3	B
/	I
4	I
and	O
Nanog	B
expression	O
is	O
required	O
to	O
sustain	O
stem	O
-	O
cell	O
pluripotency	O
and	O
both	O
of	O
these	O
markers	O
are	O
downregulated	O
as	O
cells	O
differentiate	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
4	O
-	O
9	O
]	O
.	O

Antibodies	O
to	O
Oct3	B
/	I
4	I
which	O
cross	O
react	O
with	O
human	B
Oct	I
3	I
/	I
4	I
have	O
been	O
widely	O
used	O
to	O
monitor	O
the	O
presence	O
of	O
undifferentiated	O
ESC	O
.	O

No	O
single	O
marker	O
however	O
is	O
sufficient	O
or	O
unique	O
for	O
identifying	O
ESCs	O
.	O

Oct3	B
/	I
4	I
for	O
example	O
is	O
expressed	O
by	O
germ	O
cells	O
and	O
may	O
be	O
expressed	O
by	O
specific	O
populations	O
later	O
in	O
development	O
.	O

Likewise	O
,	O
Nanog	B
has	O
been	O
shown	O
to	O
express	O
in	O
other	O
tissues	O
.	O

We	O
and	O
other	O
have	O
noted	O
however	O
,	O
that	O
while	O
no	O
single	O
marker	O
is	O
sufficient	O
a	O
constellation	O
of	O
positive	O
and	O
negative	O
markers	O
can	O
in	O
concert	O
unambiguously	O
allow	O
one	O
to	O
define	O
the	O
state	O
of	O
ESC	O
cultures	O
and	O
that	O
surface	O
markers	O
in	O
combination	O
can	O
be	O
used	O
to	O
prospectively	O
sort	O
for	O
ESC	O
.	O

Based	O
on	O
published	O
data	O
at	O
the	O
level	O
of	O
gene	O
expression	O
,	O
we	O
have	O
cloned	O
a	O
number	O
of	O
candidate	O
marker	O
genes	O
.	O

We	O
have	O
also	O
expressed	O
the	O
recombinant	O
protein	O
and	O
generated	O
a	O
panel	O
of	O
monoclonal	O
or	O
polyclonal	O
antibodies	O
to	O
these	O
proteins	O
.	O

Using	O
these	O
antibodies	O
we	O
have	O
confirmed	O
the	O
specificity	O
and	O
selectivity	O
of	O
these	O
antibodies	O
on	O
several	O
ESC	O
lines	O
and	O
established	O
their	O
utility	O
as	O
stem	O
cells	O
markers	O
.	O

Our	O
results	O
confirm	O
the	O
expression	O
pattern	O
and	O
timing	O
of	O
these	O
cell	O
markers	O
at	O
the	O
protein	O
level	O
,	O
whereas	O
previous	O
data	O
reported	O
at	O
the	O
level	O
of	O
gene	O
expression	O
.	O

Characterization	O
of	O
undifferentiated	O
human	O
ES	O
cells	O
and	O
differentiated	O
EBs	O
by	O
antibodiesAll	O
monoclonal	O
antibodies	O
were	O
initially	O
selected	O
for	O
their	O
abilities	O
to	O
recognize	O
recombinant	O
proteins	O
in	O
direct	O
ELISAs	O
.	O

A	O
subset	O
were	O
also	O
tested	O
by	O
Western	O
Blot	O
analysis	O
using	O
recombinant	O
proteins	O
and	O
cell	O
lysate	O
to	O
confirm	O
binding	O
to	O
a	O
single	O
epitope	O
.	O

The	O
best	O
clone	O
was	O
later	O
screened	O
for	O
its	O
applications	O
for	O
immunocytochemistry	O
and	O
flow	O
cytometry	O
using	O
various	O
cell	O
lines	O
.	O

Human	O
peripheral	O
blood	O
platelets	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
CD9	B
antibody	O
.	O

MCF-7	O
cells	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
E	B
-	I
Cadherin	I
and	O
PODXL	B
(	O
podocalyxin	B
-	I
like	I
)	O
antibodies	O
.	O

MG-63	O
cells	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
GATA1	B
(	O
GATA	B
binding	I
protein	I
1	I
)	O
antibody	O
.	O

Beta	O
-	O
TC6	O
cells	O
were	O
used	O
for	O
screening	O
for	O
mouse	O
anti	O
-	O
human	O
/	O
mouse	O
PDX-1	B
(	O
pancreatic	B
duodenal	I
homeobox-1	I
)	O
antibody	O
.	O

NTERA-2	O
cells	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
Oct3	B
/	I
4	I
and	O
SOX2	B
(	O
sex	B
-	I
determining	I
region	I
Y	I
-	I
box	I
2	I
)	O
antibodies	O
.	O

All	O
polyclonal	O
antibodies	O
were	O
affinity	O
-	O
purified	O
using	O
recombinant	O
proteins	O
and	O
validated	O
by	O
direct	O
ELISAs	O
and	O
Western	O
.	O

Caco-2	O
cells	O
were	O
used	O
for	O
validation	O
of	O
goat	O
anti	O
-	O
human	O
GATA6	B
antibody	O
and	O
NTERA-2	O
cells	O
were	O
used	O
for	O
validation	O
of	O
goat	O
anti	O
-	O
human	O
Nanog	B
and	O
anti	O
-	O
human	O
Oct3	B
/	I
4	I
antibodies	O
(	O
Summarized	O
in	O
Table	O
1	O
)	O
.Table	O
1Summary	O
list	O
of	O
antibody	O
verification	O
by	O
western	O
blot	O
.	O

AntibodySample	O
used	O
for	O
analysisMol	O
.	O

Wt	O
.	O

(	O
KD	O
)	O
Gt	O
×	O
hBrachyurymouse	O
ES	O
-	O
derived	O
EB	O
lysate48Ms	O
×	O
hDPPA5N	O
/	O
AN	O
/	O
AGt	O
×	O
hGATA6Caco2	O
cell	O
lysate65Gt	O
×	O
hNanogNTERA-2	O
cell	O
lysate33Gt	O
×	O
hOct	O
3	B
/	B
4NTERA-2	I
cell	O
lysate39Gt	O
×	O
hPDX1beta	O
-	O
TC	O
6	O
cell	O
lysate32Gt	O
×	O
hSOX17mouse	O
ES	O
-	O
derived	O
EB	O
lysate45Ms	O
×	O
hCD9PBMC25Rt	O
×	O
hGATA-1N	O
/	O
AN	O
/	O
AMs	O
×	O
hE	O
-	B
CadherinMCF-7	I
cell	O
lysate97Ms	O
×	O
hPODXLMCF-7	O
cell	O
lysate57Ms	O
×	O
hSOX2NTERA-2	O
cell	O
lysate36N	O
/	O
A	O
:	O
1	O
.	O

DPPA5	B
is	O
still	O
being	O
subcloned	O
.	O

Only	O
Elisa	O
verification	O
is	O
available.2	O
.	O

The	O
clone	O
for	O
GATA-1	B
(	O
MAB1779	O
)	O
does	O
not	O
work	O
for	O
Western	O
blot	O
application	O
but	O
is	O
useful	O
for	O
IHC	O
,	O
The	O
clone	O
picked	O
for	O
Western	O
blot	O
analysis	O
does	O
not	O
work	O
for	O
IHC	O
(	O
MAB17791	O
,	O
see	O
data	O
in	O
)	O
.After	O

antibodies	O
were	O
validated	O
in	O
direct	O
ELISAs	O
,	O
Western	O
blot	O
or	O
cell	O
lines	O
(	O
Fig.	O
1	O
and	O
data	O
not	O
shown	O
)	O
,	O
they	O
were	O
used	O
to	O
examine	O
the	O
expression	O
of	O
individual	O
molecules	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
and	O
differentiated	O
EBs	O
.	O

When	O
examined	O
by	O
immunohistochemistry	O
,	O
high	O
level	O
of	O
expressions	O
of	O
Oct3	B
/	I
4	I
,	O
SOX2	B
,	O
E	B
-	I
Cadherin	I
,	O
PODXL	B
and	O
Nanog	B
were	O
observed	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
(	O
Fig.	O
2A	O
,	O
2B	O
and	O
2C	O
)	O
.	O

DPPA5	B
(	O
developmental	B
pluripotency	I
associated	I
5	I
)	O
expression	O
was	O
also	O
observed	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
noted	O
that	O
a	O
subset	O
of	O
the	O
proteins	O
used	O
were	O
membrane	O
bound	O
proteins	O
.	O

To	O
test	O
if	O
any	O
of	O
the	O
antibodies	O
generated	O
could	O
recognize	O
an	O
extracellular	O
epitope	O
and	O
thus	O
be	O
used	O
for	O
live	O
cell	O
sorting	O
,	O
we	O
repeated	O
staining	O
of	O
live	O
cells	O
as	O
previously	O
described	O
.	O

The	O
CD9	B
,	O
E	B
-	I
Cadherin	I
and	O
PODXL	B
antibodies	O
recognized	O
an	O
extracellular	O
epitope	O
and	O
their	O
ability	O
to	O
select	O
cells	O
by	O
FACS	O
was	O
confirmed	O
(	O
Fig.	O
3	O
)	O
.	O

Minimal	O
or	O
no	O
expressions	O
of	O
Oct3	B
/	I
4	I
,	O
E	B
-	I
Cadherin	I
,	O
PODXL	B
and	O
Nanog	B
were	O
detected	O
in	O
the	O
differentiated	O
EBs	O
(	O
Fig.	O
2D	O
,	O
2E	O
and	O
2F	O
)	O
.	O

However	O
,	O
SOX2	B
expression	O
,	O
which	O
is	O
observed	O
in	O
neural	O
progenitor	O
cells	O
,	O
is	O
persistent	O
in	O
subsets	O
of	O
EBs	O
.	O

Figure	O
1Western	O
blot	O
analysis	O
for	O
Gt	O
×	O
hOct3	O
/	B
4	I
(	O
A	O
)	O
,	O
Gt	O
×	O
hNanog	O
(	O
B	O
)	O
and	O
Ms	O
×	O
hSOX2	O
(	O
C	O
)	O
in	O
NTERA-2	O
cell	O
lysate	O
,	O
Ms	O
×	O
hE	O
-	B
Cadherin	I
(	O
D	O
)	O
in	O
MCF-7	O
cell	O
lysate	O
,	O
Ms	O
×	O
hCD9	B
(	O
E	O
)	O
in	O
PBMC	O
lysate	O
and	O
Ms	O
×	O
hPDX-1	O
(	O
F	O
)	O
in	O
β	O
-	O
TC-6	O
cell	O
lysate	O
.	O

Numbers	O
indicate	O
the	O
positions	O
of	O
molecular	O
weight	O
markers	O
.	O

Figure	O
2Undifferentiated	O
human	O
ES	O
cells	O
(	O
A	O
,	O
B	O
,	O
and	O
C	O
)	O
and	O
differentiated	O
EBs	O
(	O
D	O
,	O
E	O
and	O
F	O
)	O
were	O
analyzed	O
using	O
antibodies	O
to	O
indicated	O
molecular	O
markers	O
.	O

Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
Oct3	B
/	I
4	I
(	O
Red	O
in	O
A	O
and	O
D	O
)	O
,	O
mouse	O
anti	O
-	O
human	O
SOX2	B
(	O
Green	O
in	O
A	O
and	O
D	O
)	O
,	O
goat	O
anti	O
-	O
human	O
E	B
-	I
Cadherin	I
(	O
Red	O
in	O
B	O
and	O
E	O
)	O
,	O
mouse	O
anti	O
-	O
human	O
PODXL	B
(	O
Green	O
in	O
B	O
and	O
E	O
)	O
,	O
and	O
goat	O
anti	O
-	O
human	O
Nanog	B
(	O
Red	O
in	O
C	O
and	O
F	O
)	O
,	O
are	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
in	O
C	O
-	O
F	O
)	O
.	O

Note	O
the	O
dramatic	O
downregulation	O
of	O
ESC	O
specific	O
markers	O
(	O
Oct3	B
/	I
4	I
,	O
E	B
-	I
Cadherin	I
,	O
PODXL	B
,	O
and	O
Nanog	B
)	O
in	O
EBs	O
.	O

However	O
,	O
SOX2	B
expression	O
is	O
persistent	O
in	O
subsets	O
of	O
EB	O
cells	O
.	O

Scale	O
bars	O
=	O
100	O
μm	O
.	O

Figure	O
3Human	O
embryonic	O
stem	O
cells	O
stained	O
with	O
anti	O
-	O
CD9	B
(	O
A	O
)	O
,	O
anti	O
-	O
E	B
-	I
Cadherin	I
(	O
B	O
)	O
,	O
and	O
anti	O
-	O
PODXL	B
(	O
C	O
)	O
and	O
antigen	O
expression	O
detected	O
by	O
a	O
flow	O
cytometer	O
.	O

The	O
specific	O
staining	O
is	O
indicated	O
by	O
green	O
histogram	O
and	O
corresponding	O
isotype	O
control	O
is	O
indicated	O
by	O
black	O
histogram	O
.	O

Suspension	O
culture	O
with	O
FGF	B
withdrawal	O
is	O
known	O
to	O
induce	O
differentiation	O
of	O
ES	O
cells	O
to	O
all	O
three	O
germ	O
layer	O
precursors	O
[	O
12	O
]	O
.	O

The	O
differentiation	O
status	O
of	O
the	O
EB	O
used	O
here	O
was	O
detected	O
to	O
contain	O
all	O
germ	O
cell	O
markers	O
by	O
RT	O
-	O
PCR	O
(	O
Fig.	O
4	O
)	O
.	O

In	O
order	O
to	O
examine	O
how	O
more	O
antibodies	O
can	O
be	O
used	O
for	O
characterization	O
of	O
early	O
differentiation	O
events	O
from	O
human	O
ES	O
cells	O
,	O
we	O
examined	O
the	O
expressions	O
of	O
endodermal	O
markers	O
,	O
SOX17	B
,	O
GATA6	B
and	O
PDX-1	B
,	O
and	O
mesodermal	O
markers	O
,	O
Brachyury	B
and	O
GATA1	B
,	O
in	O
the	O
undifferentiated	O
human	O
ES	O
cells	O
and	O
differentiated	O
EBs	O
.	O

Expressions	O
of	O
SOX17	B
,	O
GATA6	B
,	O
PDX-1	B
,	O
Brachyury	B
and	O
GATA1	B
were	O
not	O
detected	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
contrast	O
to	O
the	O
undifferentiated	O
ES	O
cells	O
,	O
subpopulations	O
of	O
SOX17-	B
,	O
GATA6-	B
,	O
Brachyury-	B
and	O
GATA1-positive	B
cells	O
were	O
observed	O
(	O
Fig	O
4	O
)	O
.	O

These	O
results	O
suggest	O
that	O
both	O
endodermal	O
and	O
mesodermal	O
precursors	O
exist	O
in	O
EBs	O
with	O
FGF	B
withdrawal	O
for	O
8	O
days	O
.	O

However	O
,	O
no	O
PDX-1-positive	B
cells	O
were	O
seen	O
in	O
EBs	O
differentiated	O
with	O
the	O
same	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.Figure	O
4Differentiated	O
EBs	O
were	O
analyzed	O
by	O
either	O
immunocytochemistry	O
or	O
RT	O
-	O
PCR	O
to	O
the	O
indicated	O
molecular	O
markers	O
.	O

(	O
A	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
SOX17	B
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
Fluoro	O
Nissl	O
nuclear	O
staining	O
(	O
Green	O
)	O
.	O

(	O
B	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
GATA6	B
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
)	O
.	O

(	O
C	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
brachyury	B
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
)	O
.	O

(	O
D	O
)	O
Immunostaining	O
with	O
mouse	O
anti	O
-	O
human	O
GATA1	B
(	O
Red	O
)	O
.	O

Note	O
that	O
each	O
antibody	O
recognizes	O
subsets	O
of	O
EB	O
cells	O
.	O

Scale	O
bars	O
=	O
100	O
μm	O
.	O

(	O
E	O
)	O
The	O
differentiation	O
status	O
of	O
EB	O
is	O
detected	O
by	O
RT	O
-	O
PCR	O
using	O
different	O
germ	O
layer	O
cell	O
markers	O
.	O

Selected	O
endoderm	O
markers	O
AFP	B
,	O
FoxA2	B
;	O
mesoderm	O
markers	O
Hand1	B
,	O
MSX1	B
and	O
ectoderm	O
marker	O
Msl1	B
were	O
all	O
highly	O
expressed	O
in	O
the	O
EB	O
samples	O
while	O
their	O
expression	O
was	O
either	O
undetectable	O
or	O
at	O
low	O
level	O
in	O
the	O
ES	O
samples	O
.	O

G3PDH	B
was	O
a	O
positive	O
control	O
showing	O
similar	O
amount	O
of	O
RNA	O
samples	O
were	O
used	O
for	O
analysis	O
.	O

Examination	O
of	O
cross	O
-	O
reactivity	O
of	O
antibodies	O
on	O
mouse	O
ES	O
and	O
differentiated	O
cellsWe	O
have	O
also	O
examined	O
the	O
cross	O
-	O
reactivities	O
of	O
these	O
antibodies	O
to	O
mouse	O
ES	O
cells	O
using	O
mouse	O
D3	O
ES	O
cell	O
line	O
and	O
mouse	O
fetal	O
endodermal	O
tissue	O
.	O

Cross	O
-	O
reactivity	O
to	O
mouse	O
of	O
goat	O
anti	O
-	O
Oct3	B
/	I
4	I
,	O
goat	O
anti	O
-	O
PDX-1	B
,	O
goat	O
anti	O
-	O
SOX17	B
and	O
mouse	O
anti	O
-	O
SOX2	B
was	O
detected	O
.	O

Minimal	O
cross	O
-	O
reactivity	O
to	O
mouse	O
,	O
measured	O
by	O
10	O
%	O
intensity	O
to	O
human	O
by	O
higher	O
than	O
control	O
cells	O
,	O
was	O
observed	O
in	O
mouse	O
anti	O
-	O
CD9	B
and	O
mouse	O
anti	O
-	O
E	B
-	I
cadherin	I
antibodies	O
.	O

Goat	O
anti	O
-	O
Nanog	B
and	O
mouse	O
anti	O
-	O
PODXL	B
antibodies	O
appear	O
to	O
be	O
human	O
-	O
specific	O
as	O
well	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
subtypes	O
of	O
monoclonal	O
antibodies	O
were	O
also	O
identified	O
in	O
the	O
best	O
clones	O
.	O

These	O
results	O
are	O
summarized	O
in	O
Table	O
2.Table	O
2Summary	O
of	O
antibodies	O
detection	O
in	O
ES	O
and	O
EB	O
samples	O
.	O

AntibodyESEBReactivity	O
to	O
mouseIsotype	O
of	O
monoclonal	O
antibody	O
(	O
Clone	O
No.	O
)	O
Gt	O
×	O
hBrachyuryNoYesNT*Ms	O
×	O
hDPPA5YesNT*NT*ND*Gt	O
×	O
hGATA6NoYesNT*Gt	O
×	O
hNanogYesDownNoGt	O
×	O
hOct	O
3	B
/	I
4YesDownYesGt	I
×	O
hPDX-1NoNoYesGt	O
×	O
hSOX17NoYesYesMs	O
×	O
hCD9YesNoMinimalMouse	O
IgG2B	B
(	O
clone	O
209306	O
)	O
Ms	O
×	O
hE	O
-	B
cadherinYesNoMinimalMouse	I
IgG2B	B
(	O
clone	O
180224	O
)	O
Ms	O
×	O
hGATA1NoYesNT*Rat	O
IgG2B	B
(	O
clone	O
234732	O
)	O
Ms	O
×	O
hPODXLYesNoNoMouse	O
IgG2A	B
(	O
clone	O
222328	O
)	O
Ms	O
×	O
hSOX2YesYesYesMouse	O
IgG2A	B
(	O
clone	O
245610	O
)	O
*NT	O
,	O
Not	O
tested	O
;	O
ND	O
,	O
Not	O
determined	O
.	O

The	O
expression	O
patterns	O
detected	O
using	O
antibodies	O
developed	O
in	O
our	O
facility	O
are	O
consistent	O
with	O
data	O
reported	O
using	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
or	O
cDNA	O
microarrays	O
.	O

Moreover	O
several	O
of	O
the	O
monoclonal	O
antibodies	O
have	O
differing	O
heavy	O
chain	O
subunits	O
allowing	O
double	O
labeling	O
using	O
subtype	O
specific	O
markers	O
to	O
be	O
performed	O
.	O

In	O
summary	O
,	O
we	O
have	O
developed	O
a	O
useful	O
collection	O
of	O
antibodies	O
that	O
would	O
be	O
useful	O
for	O
identification	O
of	O
stem	O
cell	O
characteristics	O
and	O
assessment	O
of	O
differentiation	O
.	O

Several	O
additional	O
antibodies	O
to	O
the	O
molecules	O
that	O
have	O
been	O
identified	O
as	O
potential	O
cell	O
lineage	O
markers	O
[	O
13	O
]	O
are	O
currently	O
under	O
development	O
using	O
the	O
same	O
approach	O
.	O

Cloning	O
and	O
expression	O
of	O
Brachyury	B
,	O
DPPA5	B
,	O
CD9	B
,	O
E	B
-	I
Cadherin	I
,	O
GATA1	B
,	O
GATA6	B
,	O
Nanog	B
,	O
Oct3	B
/	I
4	I
,	O
PDX-1	B
,	O
PODXL	B
,	O
SOX2	B
and	O
SOX17Brachyury	B
(	O
aa	O
.	O

1–202	O
)	O
,	O
DPPA5	B
(	O
a.a	O
.	O

1–116	O
)	O
,	O
GATA1	B
(	O
a.a	O
.	O
1–413	O
)	O
,	O
GATA6	B
(	O
aa	O
.	O

1–449	O
)	O
,	O
Nanog	B
(	O
aa	O
.	O

153–305	O
)	O
,	O
Oct3	B
/	I
4	I
(	O
aa	O
.	O
1–265	O
)	O
,	O
PDX-1	B
(	O
aa	O
.	O

1–283	O
)	O
,	O
SOX2	B
(	O
aa	O
.	O
135–317	O
)	O
and	O
SOX17	B
(	O
aa	O
.	O
177–414	O
)	O
were	O
expressed	O
in	O
E.	O
Coli	O
and	O
extracellular	O
domains	O
of	O
CD9	B
,	O
E	B
-	I
Cadherin	I
,	O
PODXL	B
were	O
expressed	O
in	O
mouse	O
NSO	O
cells	O
.	O

All	O
proteins	O
were	O
purified	O
and	O
sequenced	O
before	O
they	O
were	O
used	O
as	O
antigens	O
for	O
immunizations	O
and	O
as	O
substrate	O
for	O
antibody	O
screening	O
and	O
subcloning	O
.	O

Production	O
and	O
purification	O
of	O
antibodiesAll	O
monoclonal	O
antibodies	O
were	O
derived	O
from	O
fusions	O
of	O
mouse	O
myeloma	O
with	O
B	O
cells	O
obtained	O
from	O
BALB	O
/	O
c	O
mice	O
which	O
had	O
been	O
immunized	O
with	O
purified	O
antigen	O
.	O

The	O
IgG	B
fraction	O
of	O
the	O
culture	O
supernatant	O
was	O
purified	O
by	O
Protein	B
G	I
affinity	O
chromatography	O
(	O
Sigma	O
)	O
.	O

Each	O
panel	O
of	O
antibodies	O
was	O
screened	O
and	O
selected	O
for	O
their	O
abilities	O
to	O
detect	O
purified	O
recombinant	O
antigen	O
in	O
direct	O
ELISA	O
and	O
Western	O
blot	O
.	O

All	O
polyclonal	O
antibodies	O
were	O
derived	O
from	O
sera	O
of	O
goats	O
which	O
had	O
been	O
immunized	O
and	O
boost	O
it	O
with	O
purified	O
antigen	O
.	O

Antibody	O
was	O
purified	O
from	O
the	O
sera	O
by	O
an	O
antigen	O
-	O
affinity	O
chromatography	O
.	O

Cells	O
and	O
cell	O
cultureHuman	O
Caco-2	O
,	O
MG-63	O
,	O
MCF-7	O
,	O
NTERA-2	O
and	O
mouse	O
D3	O
cells	O
were	O
purchased	O
from	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
)	O
.	O

Cells	O
were	O
cultured	O
according	O
to	O
the	O
ATCC	O
instructions	O
.	O

Information	O
regarding	O
human	O
ES	O
cell	O
line	O
HSF-6	O
(	O
NIH	O
code	O
UC06	O
)	O
can	O
be	O
obtained	O
at	O
the	O
website	O
[	O
14	O
]	O
.	O

Undifferentiated	O
human	O
ES	O
cells	O
were	O
cultured	O
according	O
to	O
the	O
protocol	O
provided	O
by	O
the	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
in	O
human	O
ES	O
culture	O
medium	O
[	O
DMEM	O
supplemented	O
with	O
20	O
%	O
KnockOut	O
Serum	O
Replacement	O
(	O
Invitrogen	O
)	O
and	O
5	O
ng	O
/	O
mL	O
of	O
bFGF	B
(	O
R&D	O
Systems	O
)	O
]	O
.	O

To	O
induce	O
formation	O
of	O
embryoid	O
bodies	O
(	O
EBs	O
)	O
,	O
ES	O
colonies	O
were	O
harvested	O
,	O
separated	O
from	O
the	O
MEF	O
feeder	O
cells	O
by	O
gravity	O
,	O
gently	O
resuspended	O
in	O
ES	O
culture	O
medium	O
and	O
transferred	O
to	O
non	O
-	O
adherent	O
suspension	O
culture	O
dishes	O
(	O
Corning	O
)	O
.	O

Unless	O
otherwise	O
noted	O
,	O
EBs	O
derived	O
from	O
human	O
ES	O
cell	O
aggregates	O
were	O
cultured	O
for	O
8	O
days	O
in	O
ES	O
culture	O
medium	O
deprived	O
of	O
bFGF	B
and	O
used	O
for	O
analysis	O
by	O
immunohistochemistry	O
as	O
described	O
.	O

Western	O
blotCells	O
are	O
solubilized	O
in	O
hot	O
2	O
×	O
SDS	O
gel	O
sample	O
buffer	O
(	O
20	O
mM	O
dithiothreitol	O
,	O
6	O
%	O
SDS	O
,	O
0.25	O
M	O
Tris	O
,	O
pH	O
6.8	O
,	O
10	O
%	O
glycerol	O
,	O
10	O
mM	O
NaF	O
and	O
bromophenyl	O
blue	O
)	O
at	O
2	O
×	O
106	O
per	O
mL.	O
The	O
extracts	O
are	O
heated	O
in	O
a	O
boiling	O
water	O
bath	O
for	O
5	O
minutes	O
and	O
sonicated	O
with	O
a	O
probe	O
sonicator	O
with	O
3–4	O
bursts	O
of	O
5–10	O
seconds	O
each	O
.	O

Samples	O
are	O
diluted	O
with	O
1	O
×	O
SDS	O
sample	O
buffer	O
to	O
the	O
desired	O
loading	O
of	O
1–5	O
×	O
103	O
per	O
lane	O
.	O

Lysates	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
,	O
transferred	O
to	O
Immobilon	O
-	O
P	O
membrane	O
,	O
and	O
immunoblotted	O
with	O
0.5	O
μg	O
/	O
mL	O
primary	O
Abs	O
as	O
described	O
in	O
R&D	O
Systems	O
Website	O
[	O
15	O
]	O
.	O

ImmunohistochemistryAntibodies	O
were	O
used	O
with	O
the	O
appropriate	O
secondary	O
reagents	O
at	O
a	O
concentration	O
of	O
5	O
to	O
10	O
μg	O
/	O
ml	O
.	O

Cells	O
or	O
sections	O
of	O
EBs	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
in	O
PBS	O
at	O
room	O
temperature	O
for	O
20	O
min	O
,	O
then	O
blocked	O
and	O
permeabilized	O
with	O
0.1	O
%	O
Triton	O
X-100	O
,	O
1	O
%	O
BSA	O
,	O
10	O
%	O
normal	O
donkey	O
serum	O
in	O
PBS	O
at	O
room	O
temperature	O
for	O
45	O
min	O
.	O

After	O
blocking	O
,	O
cells	O
were	O
incubated	O
with	O
diluted	O
primary	O
antibody	O
overnight	O
at	O
4	O
°	O
C	O
followed	O
by	O
coupled	O
anti	O
-	O
mouse	O
or	O
anti	O
-	O
goat	O
IgG	B
(	O
Molecular	O
Probes	O
)	O
at	O
room	O
temperature	O
in	O
the	O
dark	O
for	O
an	O
hour	O
.	O

Between	O
each	O
step	O
cells	O
were	O
washed	O
with	O
PBS	O
with	O
0.1	O
%	O
BSA	O
.	O

RT	O
-	O
PCRTotal	O
RNA	O
was	O
extracted	O
from	O
EBs	O
using	O
Trizol	O
LS	O
(	O
Invitrogen	O
)	O
.	O

cDNA	O
was	O
synthesized	O
by	O
using	O
Superscript	O
II	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

The	O
PCR	O
primers	O
are	O
available	O
upon	O
request	O
.	O

Flow	O
cytometryAntibodies	O
were	O
prepared	O
at	O
the	O
concentration	O
of	O
0.1	O
mg	O
/	O
mL.	O
10	O
μL	O
of	O
the	O
stock	O
solution	O
was	O
added	O
to	O
1	O
–	O
2.5	O
×	O
105	O
cells	O
in	O
a	O
total	O
reaction	O
volume	O
not	O
exceeding	O
200	O
μL.	O
The	O
sample	O
was	O
then	O
incubated	O
for	O
20	O
min	O
at	O
2–8	O
°	O
C	O
.	O

Following	O
incubation	O
,	O
excess	O
antibody	O
was	O
removed	O
by	O
washing	O
cells	O
twice	O
with	O
FACS	O
buffer	O
(	O
2	O
%	O
FCS	O
and	O
0.1	O
%	O
sodium	O
azide	O
in	O
Hank	O
's	O
buffer	O
)	O
.	O

After	O
wash	O
,	O
cells	O
were	O
resuspend	O
in	O
200	O
μL	O
of	O
FACS	O
buffer	O
and	O
the	O
binding	O
of	O
unlabeled	O
monoclonal	O
antibodies	O
was	O
visualized	O
by	O
adding	O
10	O
μL	O
of	O
a	O
25	O
μg	O
/	O
mL	O
stock	O
solution	O
of	O
a	O
secondary	O
developing	O
reagent	O
such	O
as	O
goat	O
anti	O
-	O
mouse	O
IgG	B
conjugated	O
to	O
a	O
fluorochrome	O
for	O
20	O
min	O
at	O
2–8	O
°	O
C	O
.	O

Following	O
incubation	O
,	O
cells	O
were	O
washed	O
once	O
with	O
FACS	O
buffer	O
,	O
once	O
with	O
PBS	O
.	O

After	O
wash	O
,	O
cells	O
were	O
resuspend	O
in	O
400	O
μL	O
of	O
PBS	O
and	O
analyzed	O
on	O
a	O
FACScant	O
flow	O
cytometer	O
(	O
Becton	O
-	O
Dickinson	O
,	O
Mountain	O
View	O
,	O
CA	O
)	O
.	O

Five	O
thousand	O
events	O
were	O
collected	O
and	O
analyzed	O
using	O
CELL	O
Quest	O
software	O
.	O

BackgroundIn	O
order	O
to	O
compare	O
the	O
gene	O
expression	O
profiles	O
of	O
human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
lines	O
and	O
their	O
differentiated	O
progeny	O
and	O
to	O
monitor	O
feeder	O
contaminations	O
,	O
we	O
have	O
examined	O
gene	O
expression	O
in	O
seven	O
hESC	O
lines	O
and	O
human	O
fibroblast	O
feeder	O
cells	O
using	O
Illumina	O
®	O
bead	O
arrays	O
that	O
contain	O
probes	O
for	O
24,131	O
transcript	O
probes	O
.	O

ResultsA	O
total	O
of	O
48	O
different	O
samples	O
(	O
including	O
duplicates	O
)	O
grown	O
in	O
multiple	O
laboratories	O
under	O
different	O
conditions	O
were	O
analyzed	O
and	O
pairwise	O
comparisons	O
were	O
performed	O
in	O
all	O
groups	O
.	O

Hierarchical	O
clustering	O
showed	O
that	O
blinded	O
duplicates	O
were	O
correctly	O
identified	O
as	O
the	O
closest	O
related	O
samples	O
.	O

hESC	O
lines	O
clustered	O
together	O
irrespective	O
of	O
the	O
laboratory	O
in	O
which	O
they	O
were	O
maintained	O
.	O

hESCs	O
could	O
be	O
readily	O
distinguished	O
from	O
embryoid	O
bodies	O
(	O
EB	O
)	O
differentiated	O
from	O
them	O
and	O
the	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01V	O
.	O

The	O
embryonal	O
carcinoma	O
(	O
EC	O
)	O
line	O
NTera2	O
is	O
a	O
useful	O
model	O
for	O
evaluating	O
characteristics	O
of	O
hESCs	O
.	O

Expression	O
of	O
subsets	O
of	O
individual	O
genes	O
was	O
validated	O
by	O
comparing	O
with	O
published	O
databases	O
,	O
MPSS	O
(	O
Massively	O
Parallel	O
Signature	O
Sequencing	O
)	O
libraries	O
,	O
and	O
parallel	O
analysis	O
by	O
microarray	O
and	O
RT	O
-	O
PCR.Conclusionwe	O
show	O
that	O
Illumina	O
's	O
bead	O
array	O
platform	O
is	O
a	O
reliable	O
,	O
reproducible	O
and	O
robust	O
method	O
for	O
developing	O
base	O
global	O
profiles	O
of	O
cells	O
and	O
identifying	O
similarities	O
and	O
differences	O
in	O
large	O
number	O
of	O
samples	O
.	O

Embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
,	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
pre	O
-	O
implantation	O
embryos	O
,	O
have	O
been	O
recognized	O
as	O
the	O
most	O
pluripotent	O
stem	O
cell	O
population	O
.	O

Human	O
ES	O
cells	O
(	O
hESCs	O
)	O
can	O
be	O
maintained	O
and	O
propagated	O
on	O
mouse	O
or	O
human	O
fibroblast	O
feeders	O
for	O
extended	O
periods	O
in	O
media	O
containing	O
basic	B
fibroblast	I
growth	I
factor	I
(	O
bFGF	B
)	O
[	O
1	O
-	O
4	O
]	O
while	O
retaining	O
the	O
ability	O
to	O
differentiate	O
into	O
ectoderm	O
,	O
endoderm	O
and	O
mesoderm	O
as	O
well	O
as	O
trophoectoderm	O
and	O
germ	O
cells	O
.	O

Gene	O
expression	O
in	O
hESC	O
has	O
been	O
investigated	O
by	O
a	O
variety	O
of	O
techniques	O
including	O
massively	O
parallel	O
signature	O
sequencing	O
(	O
MPSS	O
)	O
,	O
serial	O
analysis	O
of	O
gene	O
expression	O
(	O
SAGE	O
)	O
,	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
scan	O
,	O
large	O
scale	O
microarrays	O
,	O
focused	O
cDNA	O
microarrays	O
,	O
and	O
immunocytochemistry	O
[	O
5	O
-	O
7	O
]	O
.	O

Markers	O
for	O
hESCs	O
that	O
may	O
also	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
have	O
been	O
established	O
and	O
markers	O
that	O
distinguish	O
ESCs	O
from	O
embryoid	O
bodies	O
(	O
EB	O
)	O
have	O
been	O
developed	O
.	O

Novel	O
stage	O
-	O
specific	O
genes	O
that	O
distinguish	O
between	O
hESCs	O
and	O
EBs	O
have	O
been	O
identified	O
and	O
allelic	O
differences	O
between	O
ESC	O
have	O
begun	O
to	O
be	O
recognized	O
[	O
8	O
-	O
10	O
]	O
.	O

As	O
the	O
potential	O
of	O
hESCs	O
and	O
their	O
derivatives	O
for	O
regenerative	O
medicine	O
is	O
being	O
evaluated	O
,	O
it	O
has	O
become	O
clear	O
that	O
the	O
overall	O
state	O
of	O
the	O
cells	O
,	O
degree	O
of	O
contamination	O
and	O
comparisons	O
of	O
the	O
more	O
than	O
a	O
hundred	O
different	O
newly	O
derived	O
lines	O
will	O
need	O
to	O
be	O
performed	O
.	O

It	O
will	O
be	O
necessary	O
to	O
develop	O
methods	O
to	O
monitor	O
and	O
assess	O
hESC	O
and	O
their	O
derivatives	O
on	O
a	O
routine	O
basis	O
.	O

Since	O
differentiated	O
cells	O
are	O
often	O
scattered	O
within	O
or	O
at	O
the	O
edge	O
of	O
colonies	O
[	O
11	O
]	O
and	O
the	O
differentiation	O
is	O
so	O
subtle	O
that	O
morphological	O
characteristics	O
and	O
even	O
immunohistochemistry	O
are	O
insufficient	O
to	O
detect	O
it	O
,	O
larger	O
scale	O
methods	O
of	O
analysis	O
need	O
to	O
be	O
developed	O
.	O

Our	O
strategy	O
was	O
to	O
compare	O
a	O
variety	O
of	O
different	O
hESC	O
lines	O
that	O
were	O
derived	O
and	O
expanded	O
by	O
three	O
different	O
institutions	O
(	O
WiCell	O
Research	O
Institute	O
,	O
BresaGen	O
,	O
Inc.	O
,	O
and	O
Technion	O
-	O
Israel	O
Institute	O
of	O
Technology	O
)	O
,	O
and	O
cultured	O
in	O
two	O
separate	O
laboratories	O
(	O
Burnham	O
Institute	O
and	O
NIA	O
)	O
to	O
a	O
baseline	O
set	O
of	O
data	O
against	O
which	O
cell	O
samples	O
can	O
be	O
compared	O
.	O

By	O
using	O
cells	O
grown	O
in	O
different	O
conditions	O
we	O
expected	O
to	O
be	O
able	O
to	O
identify	O
core	O
commonalities	O
and	O
by	O
comparing	O
feeders	O
and	O
embryoid	O
bodies	O
(	O
EB	O
)	O
with	O
hESC	O
identify	O
measures	O
of	O
contamination	O
and	O
early	O
markers	O
of	O
differentiation	O
.	O

Further	O
,	O
by	O
comparing	O
embryonal	O
carcinoma	O
cell	O
(	O
EC	O
)	O
and	O
karyotypically	O
variant	O
lines	O
with	O
hESC	O
,	O
we	O
would	O
be	O
able	O
to	O
directly	O
assess	O
their	O
utility	O
as	O
surrogates	O
(	O
for	O
quality	O
control	O
purposes	O
)	O
for	O
hESC	O
.	O

We	O
employed	O
a	O
pre	O
-	O
commercial	O
prototype	O
of	O
the	O
Illumina	O
HumanRef-8	O
BeadChip	O
[	O
12	O
]	O
,	O
a	O
genome	O
-	O
scale	O
bead	O
based	O
array	O
technology	O
that	O
combines	O
the	O
sensitivity	O
and	O
low	O
cost	O
of	O
a	O
focused	O
array	O
with	O
the	O
coverage	O
of	O
a	O
large	O
scale	O
array	O
,	O
while	O
requiring	O
much	O
smaller	O
sample	O
sizes	O
than	O
MPSS	O
,	O
EST	O
scan	O
or	O
SAGE	O
.	O

We	O
show	O
that	O
the	O
Illumina	O
bead	O
based	O
array	O
correctly	O
identified	O
blinded	O
duplicates	O
as	O
the	O
closest	O
related	O
samples	O
and	O
readily	O
distinguished	O
between	O
hESC	O
lines	O
,	O
as	O
well	O
as	O
between	O
ESCs	O
and	O
EBs	O
derived	O
from	O
them	O
.	O

This	O
array	O
allowed	O
us	O
to	O
estimate	O
the	O
degree	O
of	O
feeder	O
contamination	O
present	O
in	O
the	O
cultures	O
.	O

Similarities	O
and	O
differences	O
between	O
EC	O
line	O
NTera2	O
and	O
hESC	O
lines	O
could	O
be	O
determined	O
and	O
verified	O
,	O
and	O
the	O
database	O
comparisons	O
allowed	O
us	O
to	O
identify	O
core	O
self	O
-	O
renewal	O
pathways	O
that	O
regulate	O
hESC	O
propagation	O
.	O

Multiple	O
hESC	O
lines	O
can	O
be	O
assessed	O
by	O
Illumina	O
bead	O
arrayForty	O
-	O
eight	O
samples	O
were	O
selected	O
from	O
multiple	O
laboratories	O
and	O
gene	O
expression	O
profiles	O
were	O
examined	O
using	O
a	O
bead	O
array	O
containing	O
24,131	O
transcripts	O
derived	O
from	O
the	O
Human	O
RefSeq	O
database	O
that	O
included	O
full	O
length	O
and	O
splice	O
variants	O
.	O

Each	O
gene	O
was	O
represented	O
by	O
sequences	O
containing	O
an	O
average	O
of	O
thirty	O
beads	O
to	O
provide	O
an	O
internal	O
measure	O
of	O
reliability	O
.	O

Samples	O
included	O
7	O
hESC	O
lines	O
BG01	O
,	O
BG02	O
,	O
BG03	O
,	O
I6	O
,	O
H1	O
,	O
H7	O
and	O
H9	O
,	O
EBs	O
that	O
were	O
differentiated	O
from	O
hESCs	O
of	O
the	O
three	O
BG	O
lines	O
,	O
human	O
fibroblast	O
feeder	O
HS27	O
(	O
ATCC	O
)	O
,	O
hESC	O
-	O
derived	O
fibroblasts	O
,	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01	O
Variant	O
(	O
BG01V	O
)	O
[	O
13	O
]	O
and	O
EC	O
line	O
NTera2	O
[	O
14	O
]	O
.	O

Samples	O
were	O
blinded	O
and	O
biological	O
and	O
technical	O
repeats	O
were	O
examined	O
at	O
the	O
same	O
time	O
.	O

A	O
single	O
slide	O
contained	O
eight	O
replicates	O
and	O
six	O
such	O
slides	O
were	O
used	O
for	O
the	O
present	O
set	O
of	O
samples	O
.	O

Results	O
were	O
normalized	O
to	O
average	O
following	O
Illumina	O
Beadstudio	O
manual	O
and	O
the	O
quality	O
of	O
each	O
sample	O
was	O
assessed	O
by	O
immunocytochemitsry	O
and	O
RT	O
-	O
PCR	O
prior	O
to	O
subjecting	O
them	O
for	O
analysis	O
(	O
data	O
not	O
shown	O
)	O
.	O

Results	O
from	O
the	O
entire	O
sample	O
set	O
are	O
available	O
for	O
download	O
as	O
an	O
excel	O
spreadsheet	O
(	O
Additional	O
file	O
1	O
)	O
and	O
a	O
CD	O
of	O
the	O
results	O
is	O
available	O
upon	O
request	O
.	O

The	O
total	O
number	O
of	O
genes	O
identified	O
as	O
expressed	O
at	O
>	O
0.99	O
confidence	O
is	O
summarized	O
in	O
Table	O
1	O
.	O

Intensity	O
results	O
are	O
reported	O
in	O
arbitrary	O
units	O
and	O
ranged	O
from	O
10	O
to	O
20,000	O
(	O
a	O
two	O
thousand	O
fold	O
range	O
)	O
.	O

Although	O
the	O
sensitivity	O
of	O
the	O
array	O
has	O
been	O
reported	O
to	O
be	O
high	O
,	O
in	O
the	O
present	O
report	O
we	O
have	O
restricted	O
our	O
analysis	O
to	O
expression	O
of	O
at	O
least	O
100	O
units	O
in	O
any	O
one	O
sample	O
.	O

Using	O
this	O
cutoff	O
,	O
on	O
average	O
cells	O
expressed	O
approximately	O
8,000	O
transcripts	O
(	O
Table	O
1	O
,	O
2	O
)	O
,	O
a	O
number	O
similar	O
to	O
the	O
number	O
detected	O
by	O
SAGE	O
,	O
MPSS	O
and	O
EST	O
analysis	O
[	O
5	O
-	O
7,10,15,16	O
]	O
.	O

As	O
with	O
other	O
analysis	O
,	O
genes	O
with	O
the	O
highest	O
abundance	O
were	O
housekeeping	O
genes	O
,	O
ribosomal	O
genes	O
and	O
structural	O
genes	O
(	O
Table	O
2	O
and	O
Additional	O
file	O
1	O
)	O
.	O

These	O
genes	O
were	O
similar	O
in	O
most	O
samples	O
though	O
relative	O
levels	O
varied	O
.	O

Table	O
1Correlation	O
coefficients	O
of	O
paired	O
samples	O
in	O
this	O
bead	O
array	O
In	O
order	O
to	O
test	O
the	O
reproducibility	O
and	O
reliability	O
of	O
the	O
bead	O
array	O
,	O
duplicate	O
samples	O
of	O
hESC	O
lines	O
H9	O
,	O
I6	O
,	O
and	O
EC	O
line	O
NTera2	O
and	O
human	O
fibroblast	O
feeders	O
(	O
HS27	O
)	O
were	O
run	O
at	O
the	O
same	O
time	O
and	O
correlation	O
coefficients	O
(	O
R2	O
)	O
of	O
duplicates	O
were	O
generated	O
using	O
the	O
entire	O
data	O
of	O
all	O
genes	O
with	O
expression	O
level	O
>	O
0	O
(	O
§	O
)	O
,	O
or	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
(	O
*	O
)	O
,	O
or	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
and	O
expression	O
level	O
>	O
100	O
arbitrary	O
units	O
(	O
#	O
)	O
.	O

Note	O
that	O
the	O
correlation	O
coefficients	O
are	O
in	O
the	O
range	O
of	O
0.9382–0.9761	O
and	O
the	O
number	O
of	O
genes	O
was	O
in	O
the	O
range	O
of	O
10,000–14,000.Duplicate	O
SamplesNo	O
.	O
of	O
all	O
genes	O
(	O
expr.>0	O
)	O
§R2of	O
all	O
genes	O
(	O
expr	O
.	O

>	O
0	O
)	O
No	O
.	O
of	O
genes	O
(	O
>	O
0.99	O
)	O
*R2	O
of	O
genes	O
(	O
>	O
0.99	O
)	O
*No	O
.	O
(	O
>	O
0.99	O
,	O
level>100	O
)	O
#H918,8990.868113,6720.97087,408I619,1390.866312,5700.97616,826NTera219,1620.874114,0360.93827,147Feeder18,1570.872410,6060.97517,021Table	O
2Distribution	O
of	O
genes	O
with	O
expression	O
levels	O
<	O
50	O
and	O
>	O
50–10,000	O
as	O
detected	O
by	O
Illumina	O
bead	O
array	O
in	O
8	O
hESC	O
populations	O
All	O
human	O
ESC	O
samples	O
were	O
hybridized	O
in	O
one	O
experiment	O
and	O
the	O
relative	O
detection	O
levels	O
of	O
genes	O
were	O
binned	O
to	O
obtain	O
a	O
global	O
overview	O
of	O
transcription	O
,	O
approximately	O
8	O
,	O
000	O
genes	O
(	O
~50	O
%	O
)	O
were	O
greater	O
than	O
100	O
arbitrary	O
units	O
.	O

The	O
numbers	O
are	O
similar	O
to	O
results	O
obtained	O
by	O
other	O
large	O
scale	O
analysis	O
such	O
as	O
MPSS.Abundance	O
(	O
relative	O
detection	O
levels	O
)	O
H9H9	O
on	O
human	O
feedersI6BG01BG02BG03BG01VPooled	O
(	O
H1	O
,	O
H7	O
,	O
H9	O
)	O
No.%No.%No.%No.%No.%No.%No.%No.%<502,90921.26,06738.43,55925.34,52830.74,25630.54,70632.24194.35,80334.4>5010,81778.89,74761.610,48474.710,23269.39,69469.59,91567.89,43895.711,08565.6>1008,12659.27,53947.77,40952.87,70352.27,49653.77,43050.87,23073.38,21748.7>5003,07722.42,94718.62,62618.73,06520.82,95021.12,85219.52,85128.92,94117.4>10001,62911.91,62510.31,49010.61,63811.11,58911.41,51710.41,56615.91,5549.2>50002481.82571.62561.82561.72631.92621.82752.82511.5>10000900.7940.61120.8920.61000.71070.71011.0940.6Total	O
No.	O
of	O
genes	O
detected	O
at	O
>	O
0.99	O
confidence13,72615,81414,04314,76013,95014,6219,85716,888One	O
of	O
the	O
advantages	O
of	O
the	O
Illumina	O
arrays	O
is	O
the	O
ability	O
of	O
running	O
multiple	O
samples	O
simultaneously	O
thus	O
allowing	O
multiple	O
pairwise	O
comparisons	O
to	O
be	O
performed	O
readily	O
.	O

To	O
show	O
the	O
similarity	O
of	O
relative	O
gene	O
expression	O
between	O
samples	O
,	O
we	O
have	O
used	O
Illumina	O
Beadstudio	O
and	O
clustering	O
software	O
packages	O
Pcluster	O
[	O
17	O
]	O
and	O
TreeView	O
[	O
18	O
]	O
to	O
generate	O
a	O
heat	O
-	O
map	O
(	O
Figure	O
1	O
)	O
and	O
a	O
dendrogram	O
(	O
Figure	O
2	O
)	O
.	O

Based	O
on	O
their	O
properties	O
,	O
we	O
classified	O
some	O
of	O
our	O
samples	O
into	O
four	O
groups	O
,	O
(	O
A	O
)	O
undifferentiated	O
hESCs	O
(	O
including	O
a	O
sample	O
from	O
karyotypically	O
abnormal	O
variant	O
,	O
designated	O
as	O
""""	O
ES	O
""""	O
,	O
n	O
=	O
11	O
)	O
;	O
(	O
B	O
)	O
differentiated	O
ES	O
cells	O
and	O
EBs	O
(	O
designated	O
as	O
""""	O
EB	O
""""	O
,	O
n	O
=	O
6	O
)	O
;	O
(	O
C	O
)	O
hESC	O
derived	O
neural	O
cells	O
(	O
designated	O
as	O
""""	O
NS	O
""""	O
,	O
n	O
=	O
3	O
)	O
;	O
and	O
(	O
D	O
)	O
hESC	O
derived	O
mesenchyme	O
and	O
human	O
fibroblast	O
feeder	O
cells	O
(	O
designated	O
as	O
""""	O
FB	O
""""	O
,	O
n	O
=	O
5	O
)	O
and	O
these	O
groups	O
were	O
shown	O
in	O
the	O
heat	O
-	O
map	O
.	O

Comparing	O
the	O
overall	O
pattern	O
of	O
expression	O
,	O
we	O
made	O
several	O
important	O
observations	O
:	O
1	O
)	O
Duplicates	O
clustered	O
close	O
to	O
each	O
other	O
and	O
were	O
more	O
related	O
to	O
each	O
other	O
than	O
to	O
any	O
other	O
sample	O
;	O
2	O
)	O
ESCs	O
appeared	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
EBs	O
;	O
3	O
)	O
NTera2	O
cells	O
appeared	O
more	O
similar	O
to	O
ESCs	O
while	O
differentiated	O
NTera2	O
and	O
EBs	O
can	O
be	O
readily	O
distinguished	O
from	O
their	O
parent	O
populations	O
(	O
Figure	O
2	O
)	O
;	O
4	O
)	O
BG01V	O
appeared	O
similar	O
to	O
undifferentiated	O
BG01	O
cells	O
;	O
5	O
)	O
In	O
general	O
ESC	O
lines	O
grown	O
in	O
one	O
laboratory	O
appeared	O
more	O
similar	O
than	O
samples	O
grown	O
in	O
other	O
laboratories	O
,	O
suggesting	O
that	O
culture	O
conditions	O
affected	O
gene	O
expression	O
but	O
that	O
this	O
effect	O
was	O
much	O
smaller	O
than	O
the	O
effect	O
of	O
differentiation	O
.	O

Figure	O
1Unsupervised	O
two	O
-	O
way	O
hierarchical	O
cluster	O
analysis	O
of	O
differentially	O
expressed	O
genes	O
illustrated	O
in	O
a	O
heat	O
-	O
map	O
.	O

Each	O
row	O
represents	O
the	O
relative	O
levels	O
of	O
expression	O
of	O
a	O
single	O
gene	O
.	O

Each	O
column	O
represents	O
a	O
sample	O
.	O

The	O
samples	O
include	O
four	O
groups	O
of	O
cells	O
,	O
ES	O
designates	O
11	O
samples	O
of	O
hESCs	O
,	O
EB	O
contains	O
6	O
samples	O
of	O
differentiated	O
ESCs	O
and	O
EBs	O
,	O
NS	O
consists	O
of	O
3	O
hESC	O
derived	O
neural	O
cells	O
and	O
FB	O
is	O
a	O
collection	O
of	O
hESC	O
derived	O
mesenchyme	O
and	O
fibroblasts	O
.	O

High	O
expressions	O
relative	O
to	O
mean	O
are	O
colored	O
red	O
.	O

Low	O
expressions	O
are	O
colored	O
green	O
.	O

Black	O
represents	O
no	O
significant	O
change	O
in	O
expression	O
level	O
between	O
mean	O
and	O
sample	O
.	O

Samples	O
cluster	O
closer	O
within	O
their	O
own	O
group	O
than	O
samples	O
from	O
other	O
groups	O
.	O

Figure	O
2Dendrogram	O
of	O
unsupervised	O
one	O
-	O
way	O
hierarchical	O
clustering	O
analysis	O
of	O
relative	O
expression	O
of	O
genes	O
in	O
selected	O
samples	O
.	O

The	O
clustering	O
analysis	O
was	O
based	O
on	O
the	O
average	O
linkage	O
and	O
Euclidean	O
distances	O
as	O
the	O
similarity	O
metric	O
using	O
differentially	O
expressed	O
genes	O
identified	O
by	O
ANOVA	O
(	O
p	O
<	O
0.05	O
)	O
.	O

hESCs	O
clustered	O
together	O
and	O
BG	O
lines	O
cultured	O
in	O
the	O
same	O
laboratory	O
shared	O
the	O
largest	O
similarities	O
.	O

EBs	O
were	O
separated	O
from	O
hESCs	O
from	O
which	O
they	O
were	O
derived	O
.	O

EC	O
line	O
NTera2	O
and	O
feeder	O
cells	O
can	O
be	O
distinguished	O
from	O
hESCs	O
respectively	O
.	O

The	O
global	O
analysis	O
suggested	O
that	O
the	O
bead	O
arrays	O
used	O
were	O
sufficiently	O
sensitive	O
such	O
that	O
individual	O
subsets	O
of	O
genes	O
could	O
be	O
analyzed	O
,	O
different	O
populations	O
of	O
cells	O
could	O
be	O
readily	O
distinguished	O
and	O
that	O
a	O
subset	O
of	O
candidate	O
genes	O
could	O
be	O
sufficient	O
to	O
distinguish	O
between	O
groups	O
of	O
cells	O
.	O

The	O
comparison	O
across	O
multiple	O
samples	O
will	O
allow	O
a	O
set	O
of	O
core	O
stem	O
cell	O
markers	O
to	O
be	O
identified	O
.	O

In	O
subsequent	O
sections	O
we	O
have	O
performed	O
such	O
analysis	O
.	O

Readers	O
are	O
urged	O
to	O
analyze	O
the	O
expression	O
of	O
desired	O
genes	O
directly	O
as	O
it	O
is	O
impossible	O
to	O
test	O
every	O
gene	O
given	O
the	O
large	O
body	O
of	O
data	O
generated	O
.	O

Comparison	O
between	O
MPSS	O
and	O
Illumina	O
bead	O
array	O
resultsWe	O
have	O
previously	O
used	O
EST	O
scan	O
and	O
MPSS	O
to	O
analyze	O
pooled	O
samples	O
of	O
ESCs	O
and	O
EBs	O
from	O
three	O
different	O
WiCell	O
lines	O
(	O
H1	O
,	O
H7	O
and	O
H9	O
)	O
[	O
5	O
]	O
.	O

Comparison	O
between	O
the	O
two	O
methodologies	O
indicated	O
that	O
while	O
there	O
is	O
good	O
concordance	O
for	O
genes	O
expressed	O
at	O
high	O
levels	O
,	O
this	O
does	O
not	O
hold	O
for	O
genes	O
expressed	O
at	O
lower	O
levels	O
.	O

As	O
a	O
test	O
of	O
the	O
quality	O
of	O
the	O
data	O
generated	O
in	O
these	O
experiments	O
and	O
to	O
evaluate	O
whether	O
comparisons	O
can	O
be	O
made	O
across	O
different	O
methodologies	O
,	O
we	O
re	O
-	O
ran	O
the	O
identical	O
samples	O
on	O
the	O
bead	O
array	O
platform	O
.	O

The	O
complete	O
comparison	O
of	O
gene	O
expression	O
is	O
shown	O
in	O
Additional	O
file	O
2	O
and	O
is	O
summarized	O
in	O
Tables	O
3	O
and	O
Table	O
4	O
.	O

Overall	O
,	O
concordance	O
in	O
Illumina	O
array	O
was	O
better	O
than	O
that	O
evident	O
between	O
EST	O
scan	O
and	O
MPSS	O
datasets	O
[	O
9	O
]	O
,	O
but	O
clearly	O
showed	O
much	O
wider	O
differences	O
than	O
that	O
seen	O
with	O
running	O
duplicates	O
in	O
the	O
same	O
assay	O
format	O
.	O

Nevertheless	O
,	O
this	O
comparison	O
provides	O
an	O
independent	O
verification	O
of	O
the	O
data	O
and	O
suggests	O
that	O
if	O
a	O
sample	O
is	O
detected	O
in	O
more	O
than	O
one	O
large	O
-	O
scale	O
analysis	O
,	O
the	O
reliability	O
of	O
the	O
gene	O
expression	O
detection	O
is	O
high	O
,	O
which	O
also	O
reduces	O
the	O
number	O
of	O
individual	O
genes	O
needed	O
to	O
be	O
verified	O
.	O

Caution	O
should	O
be	O
observed	O
in	O
comparing	O
different	O
samples	O
run	O
on	O
different	O
platforms	O
,	O
especially	O
when	O
there	O
has	O
not	O
been	O
rigorous	O
bioinformatic	O
matching	O
of	O
the	O
source	O
sequences	O
used	O
to	O
identify	O
genes	O
in	O
the	O
platforms	O
.	O

Often	O
genes	O
called	O
by	O
the	O
same	O
symbol	O
originate	O
from	O
different	O
database	O
records	O
,	O
which	O
may	O
originate	O
from	O
different	O
splice	O
variants	O
or	O
contain	O
sequence	O
differences	O
due	O
to	O
polymorphisms	O
or	O
outright	O
error	O
[	O
19	O
]	O
.Table	O
3Expression	O
of	O
hESC	O
specific	O
markers	O
in	O
pooled	O
hESC	O
sample	O
as	O
detected	O
by	O
Illumina	O
bead	O
array	O
The	O
expression	O
of	O
previously	O
identified	O
hESC	O
markers	O
was	O
examined	O
in	O
all	O
hESC	O
samples	O
(	O
the	O
values	O
displayed	O
represent	O
the	O
expression	O
level	O
of	O
pooled	O
H1	O
,	O
H7	O
and	O
H9	O
)	O
.	O

Most	O
of	O
the	O
genes	O
were	O
also	O
identified	O
using	O
Illumina	O
bead	O
array	O
in	O
all	O
8	O
hESC	O
populations	O
in	O
this	O
study	O
(	O
1	O
*	O
)	O
,	O
the	O
gene	O
CER1	B
was	O
detected	O
in	O
all	O
except	O
one	O
duplicate	O
of	O
H9	O
(	O
2	O
*	O
)	O
,	O
Nanog	B
was	O
not	O
detected	O
in	O
all	O
populations	O
(	O
3	O
*	O
)	O
and	O
Sox2	B
,	O
Lin41	B
,	O
NR6A1	B
and	O
FoxD3	B
were	O
not	O
detected	O
in	O
the	O
array	O
although	O
they	O
were	O
present	O
in	O
the	O
chips	O
for	O
hybridization	O
(	O
4*	O
)	O
.AccessionSymbolPooled	O
ES	O
(	O
H1	O
,	O
7	O
,	O
9	O
)	O
CommentsNM_003641.1IFITM188441*NM_020997.2LEFTB6579.61*NM_024674.3LIN283944.11*NM_175849.1DNMT3B33911*NM_003212.1TDGF131691*NM_001769.2CD92930.81*NM_000165.2GJA12404.41*NM_021195.2CLDN62247.21*NM_004360.2CDH11972.91*NM_021127.1PMAIP11601.51*NM_032805.1ZNF2061504.51*NM_003577.1UTF11444.11*XM_050625.2SFRP21353.91*NM_006548.3IMP-212061*NM_152312.2GYLTL1B1066.61*NM_015973.2GAL1043.31*NM_003240.2EBAF944.11*NM_054023.2SCGB3A2890.51*NM_020990.2CKMT1742.41*NM_033668.1ITGB1694.71*NM_003744.3NUMB618.31*NM_007015.1LECT1597.41*NM_021912.2GABRB3482.71*NM_006729.2DIAPH2467.11*NM_000222.1KIT188.91*NM_005454.1CER1151.52*NM_024865.1NANOG56.93*NM_002701.1POU5F1694.41*NM_003106SOX2ND4*NM_006458.2LIN41ND4*NM_001489.3NR6A1ND4*NM_012183FOXD3ND4*Table	O
4Comparison	O
of	O
MPSS	O
and	O
Illumina	O
bead	O
array	O
results	O
The	O
samples	O
were	O
analyzed	O
by	O
MPSS	O
and	O
bead	O
array	O
.	O

The	O
number	O
of	O
genes	O
detected	O
by	O
each	O
method	O
and	O
the	O
degree	O
of	O
overlap	O
is	O
summarized	O
.	O

Note	O
much	O
higher	O
degree	O
of	O
overlap	O
when	O
the	O
top	O
2000	O
hits	O
were	O
compared	O
.	O

*	O
:	O
Most	O
of	O
the	O
genes	O
detected	O
by	O
MPSS	O
were	O
novel	O
genes	O
not	O
included	O
in	O
the	O
bead	O
array	O
.	O

ESNo.%Common	O
in	O
both	O
(	O
Top	O
2000	O
hits	O
)	O
1,62281.1Common	O
in	O
both	O
(	O
All	O
hits	O
)	O
5,07146.0By	O
bead	O
array	O
only3,46231.4By	O
MPSS	O
only	O
*	O
2,50422.7Total11,037100EBNo.%Common	O
in	O
both	O
(	O
All	O
hits	O
)	O
5,16843.1By	O
bead	O
array	O
only4,13134.4By	O
MPSS	O
only	O
*	O
2,69422.5Total11,993100	O
Human	O
feeders	O
and	O
hESCs	O
can	O
be	O
readily	O
distinguished	O
and	O
contamination	O
can	O
be	O
readily	O
assessedFor	O
all	O
samples	O
,	O
we	O
conducted	O
an	O
unsupervised	O
one	O
-	O
way	O
hierarchical	O
clustering	O
analysis	O
.	O

The	O
clustering	O
analysis	O
was	O
based	O
on	O
the	O
average	O
linkage	O
and	O
Euclidean	O
distances	O
as	O
the	O
similarity	O
metric	O
using	O
differentially	O
expressed	O
genes	O
identified	O
by	O
ANOVA	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
analysis	O
revealed	O
the	O
underlying	O
features	O
and	O
variation	O
patterns	O
of	O
gene	O
expression	O
in	O
each	O
cell	O
types	O
.	O

Figure	O
2	O
shows	O
results	O
of	O
the	O
cluster	O
analysis	O
of	O
relative	O
gene	O
expression	O
in	O
selected	O
samples	O
.	O

As	O
one	O
of	O
our	O
purposes	O
of	O
this	O
study	O
was	O
to	O
distinguish	O
between	O
human	O
fibroblast	O
feeders	O
cells	O
and	O
hESCs	O
and	O
hEBs	O
,	O
wishing	O
to	O
readily	O
detect	O
feeder	O
contamination	O
in	O
hESCs	O
,	O
we	O
included	O
one	O
of	O
the	O
human	O
feeder	O
cells	O
HS27	O
(	O
ATCC	O
)	O
in	O
this	O
study	O
.	O

We	O
have	O
been	O
using	O
HS27	O
as	O
feeder	O
cells	O
for	O
H9	O
hESCs	O
for	O
more	O
than	O
two	O
years	O
and	O
all	O
hESCs	O
grown	O
on	O
HS27	O
had	O
normal	O
karyotype	O
,	O
expressed	O
all	O
undifferentiated	O
markers	O
,	O
and	O
made	O
teratomas	O
with	O
all	O
germ	O
layers	O
(	O
data	O
not	O
show	O
)	O
.	O

The	O
global	O
pairwise	O
comparison	O
clearly	O
showed	O
that	O
human	O
feeders	O
were	O
far	O
more	O
dissimilar	O
to	O
hESCs	O
than	O
hESCs	O
grown	O
in	O
different	O
laboratories	O
,	O
hESCs	O
compared	O
to	O
their	O
differentiated	O
EBs	O
that	O
contained	O
mesodermal	O
tissue	O
,	O
and	O
hESCs	O
compared	O
to	O
the	O
karyotypically	O
variant	O
hESC	O
line	O
BG01V	O
.	O

Pairwise	O
comparisons	O
of	O
human	O
feeders	O
with	O
hESCs	O
resulted	O
in	O
a	O
correlation	O
coefficient	O
of	O
0.66	O
,	O
which	O
was	O
less	O
than	O
the	O
correlation	O
coefficient	O
of	O
0.71–0.74	O
observed	O
between	O
hESCs	O
and	O
their	O
corresponding	O
EBs	O
.	O

The	O
large	O
difference	O
between	O
human	O
feeders	O
and	O
hESCs	O
suggested	O
that	O
it	O
would	O
be	O
possible	O
to	O
identify	O
markers	O
that	O
were	O
robust	O
and	O
reliable	O
in	O
distinguishing	O
the	O
two	O
populations	O
,	O
and	O
these	O
markers	O
would	O
be	O
sufficiently	O
sensitive	O
in	O
detecting	O
contamination	O
of	O
feeders	O
.	O

We	O
examined	O
the	O
data	O
to	O
develop	O
a	O
list	O
of	O
genes	O
that	O
had	O
high	O
levels	O
of	O
expression	O
in	O
human	O
feeder	O
cells	O
maintained	O
in	O
hESC	O
medium	O
but	O
whose	O
expression	O
was	O
low	O
or	O
absent	O
in	O
either	O
ESCs	O
or	O
EBs	O
.	O

The	O
absence	O
of	O
expression	O
in	O
EBs	O
was	O
used	O
as	O
a	O
control	O
for	O
spontaneous	O
differentiation	O
of	O
ESC	O
colonies	O
(	O
including	O
mesodermal	O
differentiation	O
)	O
which	O
may	O
occur	O
and	O
the	O
markers	O
selected	O
should	O
be	O
able	O
to	O
distinguish	O
between	O
these	O
two	O
events	O
.	O

A	O
complete	O
list	O
of	O
genes	O
expressed	O
at	O
least	O
ten	O
-	O
fold	O
higher	O
in	O
human	O
feeders	O
is	O
provided	O
in	O
Figure	O
3	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
(	O
qPCR	O
)	O
was	O
used	O
to	O
verify	O
the	O
fold	O
change	O
of	O
the	O
expression	O
of	O
4	O
genes	O
,	O
including	O
THBS1	B
,	O
MMP3	B
,	O
TNFRSF11B	B
and	O
KRTHA4	B
(	O
Figure	O
3C	O
)	O
.	O

Further	O
confirmation	O
can	O
also	O
be	O
done	O
using	O
immunocytochemistry	O
,	O
as	O
antibodies	O
against	O
these	O
genes	O
are	O
commercially	O
available	O
.	O

Figure	O
3Human	O
fibroblast	O
feeder	O
cells	O
can	O
be	O
distinguished	O
from	O
hESCs	O
and	O
EBs	O
.	O

Bead	O
array	O
identified	O
lists	O
of	O
genes	O
that	O
were	O
uniquely	O
expressed	O
in	O
human	O
fibroblast	O
feeders	O
as	O
compared	O
to	O
hESCs	O
(	O
A	O
)	O
and	O
hEBs	O
(	O
B	O
)	O
.	O

The	O
four	O
genes	O
whose	O
expression	O
was	O
confirmed	O
by	O
qPCR	O
(	O
C	O
)	O
were	O
in	O
bold	O
.	O

In	O
the	O
graph	O
(	O
C	O
)	O
,	O
gene	O
expression	O
of	O
each	O
gene	O
in	O
feeder	O
cells	O
was	O
designated	O
as	O
1	O
fold	O
and	O
the	O
bars	O
represented	O
fold	O
decrease	O
for	O
each	O
gene	O
.	O

Thus	O
this	O
comparison	O
allowed	O
us	O
to	O
distinguish	O
between	O
hESCs	O
and	O
human	O
feeders	O
and	O
identify	O
candidate	O
markers	O
that	O
could	O
detect	O
feeder	O
cell	O
contamination	O
should	O
human	O
feeders	O
be	O
used	O
in	O
the	O
propagation	O
of	O
hESCs	O
.	O

hESCs	O
and	O
EBs	O
can	O
be	O
distinguished	O
from	O
each	O
otherIllumina	O
bead	O
array	O
analysis	O
confirmed	O
that	O
hESCs	O
could	O
be	O
readily	O
distinguished	O
from	O
EBs	O
by	O
global	O
analysis	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
specific	O
subsets	O
of	O
markers	O
could	O
be	O
identified	O
.	O

We	O
and	O
others	O
have	O
used	O
MPSS	O
and	O
EST	O
scan	O
and	O
generated	O
array	O
data	O
to	O
make	O
lists	O
of	O
hESC	O
-	O
specific	O
genes	O
[	O
5,9,10,20	O
]	O
.	O

As	O
discussed	O
above	O
,	O
most	O
hESC	O
markers	O
identified	O
by	O
MPSS	O
have	O
been	O
detected	O
in	O
the	O
present	O
bead	O
array	O
analysis	O
(	O
Table	O
3	O
)	O
,	O
confirming	O
the	O
utility	O
of	O
these	O
previously	O
identified	O
markers	O
for	O
use	O
in	O
assessing	O
undifferentiated	O
status	O
of	O
hESCs	O
.	O

In	O
addition	O
,	O
we	O
have	O
generated	O
a	O
list	O
of	O
genes	O
differentially	O
expressed	O
at	O
higher	O
level	O
in	O
EBs	O
than	O
in	O
hESCs	O
,	O
a	O
subset	O
of	O
which	O
is	O
shown	O
in	O
Table	O
5	O
.	O

These	O
markers	O
were	O
common	O
to	O
all	O
EB	O
samples	O
tested	O
and	O
included	O
genes	O
known	O
to	O
be	O
expressed	O
in	O
ectoderm	O
,	O
endoderm	O
and	O
mesoderm	O
.	O

The	O
entire	O
set	O
of	O
differentially	O
expressed	O
genes	O
is	O
provided	O
in	O
Additional	O
file	O
3	O
.	O

Thus	O
,	O
the	O
bead	O
array	O
format	O
,	O
which	O
allows	O
multiple	O
pairwise	O
comparisons	O
,	O
can	O
be	O
used	O
to	O
identify	O
genes	O
that	O
are	O
expressed	O
by	O
all	O
differentiating	O
EB	O
samples	O
in	O
the	O
present	O
study	O
.	O

Our	O
data	O
suggested	O
that	O
a	O
core	O
set	O
of	O
limited	O
markers	O
might	O
be	O
sufficient	O
to	O
monitor	O
the	O
process	O
of	O
differentiation	O
.	O

By	O
suitable	O
selection	O
of	O
different	O
germ	O
cell	O
layer	O
specific	O
markers	O
one	O
may	O
also	O
assess	O
the	O
overall	O
quality	O
of	O
differentiation	O
toward	O
germ	O
cells	O
.	O

Table	O
5Genes	O
which	O
are	O
differentially	O
expressed	O
at	O
higher	O
levels	O
in	O
EBs	O
than	O
in	O
hESCsSymbolAll	O
EBAll	O
ESEB	O
/	O
ESRELN11120.52224.0SST1394.25.5253.5SLC40A11210.19.1133.0IGF24896.938.4127.5SLN2017.817118.7DCN7588.176.299.6ANXA84048.941.996.6AQP11665.420.581.2APOB1256.415.879.5AHSG1414.320.868.0NID21476.731.447.0FGB221052.442.2LUM8439.4205.441.1MGP2772.469.839.7THBD1206.434.435.1SERPINA11255.643.728.7HAND112294437.428.1HBE11106.542.626.0TTR7661.2347.122.1HBG21601.185.618.7COL2A11636.291.817.8KIAA09771370.87817.6AFP8941552.316.2COL3A11355796714.0IGFBP38446.3603.414.0PAX61577.8118.213.3APOA19398.1709.813.2FRZB3523.7315.711.2SPON21548.7159.49.7CEBPD1100.2122.79.0DLK13355.8374.89.0RDC11589.7192.18.3BMP41851.5227.38.1PITX21057.9131.28.1ACTA25045629.88.0GAS11215.61547.9AGTRL11053.8135.17.8COL5A15876.4765.47.7CDKN1C3134.1412.97.6CXCL142220.5312.67.1DOK41011.1145.27.0ARHGDIB1635.3246.56.6FLRT21879.5314.36.0MSX12771.8499.75.5	O
Smaller	O
but	O
distinct	O
differences	O
among	O
undifferentiated	O
hESC	O
linesOur	O
cluster	O
analysis	O
indicated	O
that	O
BG01	O
,	O
BG02	O
and	O
BG03	O
cell	O
lines	O
were	O
overall	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
other	O
lines	O
(	O
Figure	O
1	O
and	O
2	O
)	O
,	O
but	O
nevertheless	O
showed	O
additional	O
differences	O
than	O
technical	O
or	O
biological	O
repeats	O
of	O
the	O
same	O
sample	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
this	O
microarray	O
strategy	O
may	O
be	O
sufficiently	O
sensitive	O
to	O
identify	O
relatively	O
cell	O
type	O
specific	O
candidate	O
genes	O
that	O
could	O
be	O
used	O
to	O
distinguish	O
one	O
hESC	O
population	O
from	O
another	O
or	O
to	O
identify	O
differences	O
that	O
were	O
due	O
to	O
varied	O
isolation	O
and	O
growth	O
conditions	O
.	O

As	O
a	O
test	O
we	O
looked	O
for	O
differences	O
between	O
BG01	O
,	O
BG02	O
and	O
BG03	O
,	O
which	O
were	O
grown	O
in	O
the	O
same	O
laboratory	O
under	O
the	O
same	O
conditions	O
.	O

Lists	O
of	O
candidate	O
genes	O
are	O
shown	O
in	O
Figure	O
4A	O
,	O
C	O
and	O
4E	O
and	O
the	O
comparison	O
of	O
these	O
three	O
lines	O
are	O
shown	O
in	O
scatter	O
plots	O
in	O
Figure	O
4B	O
,	O
D	O
and	O
4F.Figure	O
4BG	O
lines	O
show	O
small	O
but	O
distinct	O
differences	O
as	O
assessed	O
by	O
bead	O
array	O
.	O

These	O
three	O
hESC	O
lines	O
share	O
high	O
similarities	O
as	O
shown	O
by	O
the	O
scatterplots	O
of	O
BG01	O
vs	O
BG02	O
(	O
B	O
)	O
,	O
BG01	O
vs	O
BG03	O
(	O
D	O
)	O
and	O
BG02	O
vs	O
BG03	O
(	O
F	O
)	O
.	O

Comparisons	O
of	O
all	O
three	O
lines	O
were	O
made	O
and	O
lists	O
of	O
selected	O
genes	O
that	O
were	O
specifically	O
expressed	O
in	O
BG01	O
(	O
A	O
)	O
,	O
BG02	O
(	O
C	O
)	O
and	O
BG03	O
(	O
F	O
)	O
are	O
shown	O
.	O

Correlation	O
coefficients	O
(	O
R2	O
)	O
were	O
generated	O
using	O
all	O
genes	O
with	O
expression	O
level	O
>	O
0	O
(	O
black	O
and	O
blue	O
dots	O
)	O
,	O
or	O
all	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
(	O
blue	O
dots	O
)	O
.	O

Genes	O
outside	O
the	O
two	O
thin	O
red	O
lines	O
were	O
detected	O
at	O
>	O
2.5-	O
fold	O
difference	O
.	O

We	O
reasoned	O
as	O
well	O
that	O
such	O
a	O
global	O
comparison	O
should	O
allow	O
us	O
to	O
distinguish	O
between	O
male	O
and	O
female	O
lines	O
if	O
genes	O
present	O
on	O
the	O
Y	O
chromosome	O
were	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
undifferentiated	O
state	O
and	O
were	O
detected	O
by	O
the	O
bead	O
array	O
.	O

Several	O
such	O
candidate	O
genes	O
were	O
identified	O
.	O

The	O
most	O
robust	O
were	O
RPS4Y	B
,	O
RPS4Y2	B
,	O
and	O
EIF1AY	B
(	O
Figure	O
5	O
)	O
.	O

To	O
confirm	O
that	O
these	O
were	O
useful	O
markers	O
,	O
we	O
designed	O
RT	O
-	O
PCR	O
primers	O
and	O
tested	O
their	O
expression	O
in	O
a	O
male	O
(	O
BG01	O
)	O
and	O
a	O
female	O
(	O
BG03	O
)	O
line	O
(	O
Figure	O
5B	O
)	O
.	O

We	O
noted	O
that	O
several	O
of	O
these	O
continued	O
to	O
be	O
expressed	O
at	O
high	O
levels	O
as	O
ESCs	O
differentiated	O
to	O
form	O
EBs	O
and	O
upon	O
further	O
differentiation	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
these	O
markers	O
might	O
be	O
used	O
in	O
adult	O
stem	O
cell	O
and	O
germ	O
cell	O
populations	O
as	O
well	O
.	O

Figure	O
5Male	O
and	O
female	O
hESC	O
lines	O
can	O
be	O
distinguished	O
by	O
genes	O
identified	O
by	O
bead	O
array	O
.	O

Five	O
potential	O
genes	O
RPS4Y	B
,	O
RPS4Y2	B
,	O
EIF1AY	B
,	O
VCY	B
,	O
and	O
AMELY	B
are	O
located	O
in	O
the	O
Y	O
chromosome	O
.	O

By	O
comparing	O
the	O
expression	O
level	O
of	O
these	O
genes	O
in	O
all	O
hESC	O
lines	O
,	O
we	O
have	O
found	O
that	O
3	O
out	O
of	O
5	O
were	O
specifically	O
expressed	O
in	O
male	O
hESC	O
lines	O
I6	O
,	O
BG01	O
and	O
BG02	O
(	O
A	O
)	O
and	O
this	O
was	O
verified	O
by	O
RT	O
-	O
PCR	O
in	O
male	O
line	O
BG01	O
and	O
female	O
line	O
BG03	O
(	O
B	O
)	O
.	O

G3PDH	B
was	O
used	O
as	O
an	O
internal	O
control	O
.	O

*	O
:	O
represents	O
the	O
gene	O
expression	O
level	O
is	O
detected	O
at	O
<	O
0.99	O
confidence	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
the	O
bead	O
array	O
format	O
is	O
sufficiently	O
sensitive	O
and	O
global	O
that	O
it	O
can	O
distinguish	O
one	O
cell	O
line	O
from	O
another	O
even	O
if	O
those	O
two	O
cell	O
lines	O
are	O
grown	O
in	O
the	O
same	O
laboratory	O
under	O
virtually	O
identical	O
conditions	O
.	O

Bead	O
array	O
can	O
also	O
be	O
used	O
to	O
distinguish	O
between	O
male	O
and	O
female	O
lines	O
.	O

Comparison	O
of	O
diploid	O
pluripotent	O
cells	O
with	O
NTera2	O
and	O
BG01	O
variantOur	O
previous	O
results	O
have	O
suggested	O
that	O
EC	O
lines	O
share	O
many	O
of	O
the	O
properties	O
of	O
hESCs	O
and	O
can	O
be	O
used	O
as	O
a	O
useful	O
model	O
for	O
initial	O
testing	O
of	O
biological	O
questions	O
[	O
21	O
]	O
.	O

More	O
recently	O
we	O
have	O
identified	O
BG01V	O
as	O
a	O
karyotypically	O
abnormal	O
variant	O
that	O
behaves	O
much	O
like	O
its	O
normal	O
counterpart	O
BG01	O
,	O
but	O
is	O
not	O
subject	O
to	O
the	O
same	O
constraints	O
of	O
use	O
as	O
karyotypically	O
normal	O
hESCs	O
[	O
13	O
]	O
.	O

Given	O
the	O
sensitivity	O
of	O
the	O
bead	O
array	O
analysis	O
,	O
we	O
tested	O
its	O
ability	O
to	O
detect	O
the	O
overall	O
similarities	O
and	O
differences	O
between	O
NTera2	O
and	O
a	O
pooled	O
ESC	O
sample	O
or	O
between	O
the	O
karyotypically	O
abnormal	O
BG01V	O
and	O
its	O
normal	O
parent	O
line	O
(	O
Figure	O
6	O
)	O
.Figure	O
6Diploid	O
pluripotent	O
EC	O
cell	O
line	O
NTera2	O
and	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01V	O
can	O
be	O
distinguished	O
from	O
normal	O
hESCs	O
using	O
Illumina	O
array	O
.	O

Comparison	O
of	O
NTera2	O
and	O
pooled	O
hESC	O
sample	O
resulted	O
a	O
correlation	O
coefficient	O
of	O
0.8997	O
.	O

Two	O
lists	O
of	O
genes	O
,	O
which	O
were	O
specifically	O
expressed	O
in	O
NTera2	O
(	O
C	O
)	O
or	O
in	O
hESCs	O
(	O
E	O
)	O
were	O
identified	O
.	O

Likewise	O
,	O
while	O
sharing	O
similarities	O
with	O
BG01	O
(	O
B	O
,	O
correlation	O
coefficient=	O
0.9043	O
)	O
,	O
BG01V	O
was	O
different	O
from	O
BG01	O
in	O
expression	O
for	O
many	O
genes	O
,	O
particularly	O
genes	O
from	O
the	O
TGFβ	B
pathway	O
(	O
D	O
,	O
F	O
)	O
.	O

Black	O
dots	O
represent	O
genes	O
that	O
were	O
detected	O
at	O
>	O
0	O
expression	O
level	O
,	O
blue	O
dots	O
represent	O
genes	O
that	O
were	O
detected	O
both	O
at	O
>	O
0	O
expression	O
level	O
and	O
at	O
>	O
0.99	O
confidence	O
.	O

Genes	O
plotted	O
outside	O
the	O
two	O
thin	O
red	O
lines	O
were	O
detected	O
at	O
>	O
2.5-	O
fold	O
difference	O
.	O

Our	O
results	O
showed	O
that	O
,	O
while	O
NTera2	O
shared	O
a	O
high	O
similarity	O
with	O
hESCs	O
[	O
21	O
]	O
,	O
it	O
did	O
have	O
important	O
differences	O
with	O
hESC	O
lines	O
.	O

Examining	O
these	O
differences	O
(	O
summarized	O
in	O
Figure	O
6C	O
and	O
6E	O
)	O
,	O
we	O
noted	O
that	O
some	O
reflected	O
the	O
origin	O
of	O
the	O
tumor	O
cells	O
from	O
which	O
this	O
line	O
was	O
derived	O
[	O
14	O
]	O
.	O

Several	O
germ	O
cell	O
markers	O
such	O
as	O
GAGE2	B
,	O
GAGE7	B
and	O
GAGE8	B
were	O
highly	O
expressed	O
in	O
NTera2	O
but	O
were	O
absent	O
(	O
or	O
present	O
at	O
low	O
levels	O
)	O
in	O
any	O
of	O
the	O
hESC	O
lines	O
examined	O
(	O
See	O
Figure	O
6C	O
and	O
Additional	O
file	O
1	O
.	O

Note	O
that	O
the	O
GAGE	B
genes	O
are	O
highly	O
similar	O
in	O
sequence	O
,	O
making	O
it	O
difficult	O
to	O
distinguish	O
one	O
family	O
member	O
from	O
another	O
through	O
hybridization	O
;	O
thus	O
,	O
while	O
all	O
of	O
these	O
GAGE	O
gene	O
probes	O
gave	O
positive	O
signal	O
,	O
it	O
is	O
difficult	O
to	O
say	O
if	O
the	O
signal	O
came	O
from	O
the	O
specific	O
gene	O
itself	O
or	O
from	O
cross	O
-	O
hybridization	O
from	O
one	O
of	O
the	O
other	O
family	O
members	O
)	O
.	O

None	O
of	O
these	O
were	O
present	O
in	O
BG01V	O
,	O
indicating	O
that	O
the	O
karyotypically	O
abnormal	O
variant	O
is	O
not	O
the	O
equivalent	O
of	O
a	O
teratocarcinoma	O
line	O
such	O
as	O
NTera2	O
.	O

In	O
addition	O
to	O
the	O
expression	O
of	O
germ	O
cell	O
markers	O
,	O
we	O
noticed	O
a	O
significant	O
difference	O
in	O
the	O
expression	O
of	O
genes	O
in	O
the	O
TGFβ	B
pathway	O
,	O
such	O
as	O
GDF3	B
(	O
Figure	O
6C	O
)	O
,	O
TGFBI	B
,	O
CDKN1A	B
,	O
IGFBP7	B
,	O
IGFBP3	B
,	O
NODAL	B
,	O
CER1	B
and	O
BMP2	B
(	O
Figure	O
6E	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
postulated	O
role	O
of	O
this	O
pathway	O
in	O
germ	O
cell	O
differentiation	O
[	O
22,23	O
]	O
and	O
suggests	O
that	O
TGFβ	B
pathway	O
can	O
not	O
be	O
reliably	O
tested	O
using	O
NTera2	O
as	O
a	O
model	O
for	O
hESC.The	O
BG01V	O
showed	O
clear	O
differences	O
from	O
its	O
normal	O
counterpart	O
and	O
some	O
major	O
changes	O
are	O
summarized	O
in	O
Figure	O
6D	O
and	O
6F	O
.	O

Early	O
markers	O
of	O
differentiation	O
appeared	O
to	O
be	O
present	O
at	O
higher	O
levels	O
in	O
BG01V	O
as	O
compared	O
to	O
any	O
of	O
the	O
hESC	O
lines	O
examined	O
,	O
although	O
hESC	O
specific	O
genes	O
continued	O
to	O
be	O
expressed	O
at	O
high	O
levels	O
(	O
see	O
Additional	O
file	O
4	O
)	O
.	O

In	O
particular	O
,	O
the	O
Wnt	B
pathway	O
and	O
the	O
TGFβ	B
signaling	O
pathway	O
(	O
Figure	O
6D	O
)	O
,	O
both	O
of	O
which	O
involved	O
in	O
the	O
early	O
process	O
of	O
differentiation	O
[	O
24,25	O
]	O
,	O
appeared	O
to	O
be	O
activated	O
(	O
Additional	O
file	O
4	O
)	O
,	O
suggesting	O
that	O
the	O
role	O
of	O
growth	O
factors	O
and	O
signaling	O
in	O
these	O
early	O
events	O
can	O
not	O
be	O
readily	O
studied	O
in	O
this	O
cell	O
line	O
.	O

In	O
summary	O
,	O
the	O
analysis	O
highlighted	O
the	O
utility	O
of	O
the	O
potential	O
reference	O
standards	O
NTera2	O
and	O
BG01V	O
,	O
demonstrated	O
their	O
general	O
similarity	O
and	O
provided	O
detail	O
on	O
potential	O
caveats	O
to	O
their	O
application	O
.	O

Global	O
arrays	O
provide	O
a	O
snapshot	O
of	O
the	O
state	O
of	O
the	O
cells	O
and	O
identify	O
core	O
self	O
-	O
renewal	O
pathwaysWe	O
have	O
utilized	O
a	O
small	O
fraction	O
of	O
the	O
data	O
to	O
demonstrate	O
the	O
overall	O
utility	O
of	O
this	O
approach	O
and	O
its	O
sensitivity	O
in	O
identifying	O
small	O
differences	O
in	O
cell	O
populations	O
.	O

An	O
additional	O
potential	O
application	O
of	O
such	O
an	O
analysis	O
is	O
the	O
ability	O
to	O
examine	O
the	O
general	O
state	O
of	O
a	O
particular	O
signaling	O
pathway	O
and	O
determine	O
whether	O
it	O
is	O
active	O
.	O

By	O
comparing	O
across	O
many	O
samples	O
,	O
a	O
procedure	O
previously	O
expensive	O
and	O
difficult	O
in	O
terms	O
of	O
the	O
RNA	O
and	O
replicate	O
requirement	O
,	O
one	O
can	O
rapidly	O
identify	O
key	O
regulatory	O
pathways	O
.	O

To	O
test	O
whether	O
we	O
could	O
use	O
such	O
multiple	O
pairwise	O
comparisons	O
to	O
elucidate	O
the	O
major	O
regulatory	O
pathways	O
that	O
may	O
be	O
required	O
for	O
hESC	O
self	O
-	O
renewal	O
,	O
we	O
examined	O
several	O
metabolic	O
pathways	O
.	O

The	O
results	O
of	O
the	O
analysis	O
of	O
the	O
insulin	B
/	O
insulin	B
-	I
like	I
growth	I
factor	I
(	O
IGF	B
)	O
signaling	O
pathway	O
are	O
shown	O
in	O
Figure	O
7	O
.	O

Using	O
the	O
same	O
4	O
groups	O
of	O
samples	O
as	O
in	O
Figure	O
1	O
,	O
we	O
conducted	O
PAM	O
(	O
Prediction	O
Analysis	O
of	O
Microarray	O
)	O
[	O
26	O
]	O
,	O
in	O
search	O
for	O
biomarkers	O
used	O
in	O
diagnostic	O
identification	O
of	O
these	O
four	O
groups	O
,	O
ES	O
,	O
EB	O
,	O
NS	O
,	O
and	O
FB	O
.	O

In	O
PAM	O
,	O
a	O
list	O
of	O
significant	O
IGF	B
pathway	O
genes	O
whose	O
expression	O
characterizes	O
each	O
diagnostic	O
class	O
was	O
obtained	O
.	O

The	O
average	O
gene	O
expression	O
level	O
in	O
each	O
class	O
was	O
divided	O
by	O
the	O
within	O
-	O
class	O
standard	O
deviation	O
.	O

The	O
nearest	O
centroid	O
classification	O
computed	O
took	O
the	O
gene	O
expression	O
profile	O
from	O
a	O
new	O
sample	O
and	O
compared	O
it	O
to	O
each	O
of	O
these	O
class	O
centroids	O
.	O

For	O
cross	O
-	O
validation	O
of	O
prediction	O
results	O
,	O
multiple	O
classification	O
processes	O
were	O
performed	O
on	O
two	O
data	O
sets	O
randomly	O
constructed	O
each	O
time	O
from	O
the	O
entire	O
gene	O
expression	O
dataset	O
.	O

The	O
first	O
dataset	O
,	O
consisting	O
of	O
70	O
%	O
of	O
the	O
total	O
data	O
,	O
was	O
used	O
as	O
the	O
training	O
dataset	O
,	O
and	O
the	O
other	O
dataset	O
,	O
containing	O
the	O
remaining	O
30	O
%	O
of	O
data	O
,	O
was	O
used	O
for	O
the	O
data	O
prediction	O
and	O
verification	O
process	O
.	O

The	O
final	O
biomarkers	O
were	O
determined	O
in	O
such	O
a	O
way	O
that	O
the	O
misclassification	O
error	O
rate	O
was	O
minimal	O
.	O

The	O
resulting	O
graph	O
(	O
Figure	O
7	O
)	O
showed	O
the	O
shrunken	O
class	O
centroids	O
for	O
genes	O
that	O
had	O
at	O
least	O
one	O
nonzero	O
difference	O
in	O
each	O
diagnostic	O
class	O
.	O

The	O
genes	O
with	O
nonzero	O
components	O
in	O
each	O
class	O
were	O
almost	O
mutually	O
exclusive	O
and	O
represented	O
candidate	O
biomarkers	O
for	O
the	O
diagnosis	O
of	O
each	O
class	O
.	O

All	O
data	O
analyses	O
were	O
performed	O
using	O
the	O
bioconductor	O
package	O
[	O
17	O
]	O
.Figure	O
7Identification	O
of	O
diagnostic	O
markers	O
by	O
PAM	O
.	O

The	O
shrunken	O
class	O
centroids	O
for	O
genes	O
which	O
have	O
at	O
least	O
one	O
nonzero	O
difference	O
are	O
shown	O
.	O

The	O
genes	O
with	O
nonzero	O
components	O
in	O
each	O
class	O
were	O
almost	O
mutually	O
exclusive	O
and	O
were	O
the	O
candidate	O
molecular	O
markers	O
for	O
the	O
diagnosis	O
of	O
the	O
four	O
groups	O
of	O
cell	O
populations	O
,	O
including	O
,	O
(	O
from	O
left	O
to	O
right	O
)	O
hESC	O
derived	O
mesenchyme	O
and	O
human	O
fibroblast	O
feeder	O
cells	O
(	O
""""	O
FB	O
""""	O
,	O
n	O
=	O
5	O
)	O
,	O
undifferentiated	O
hESCs	O
(	O
""""	O
ES	O
""""	O
,	O
n	O
=	O
11	O
)	O
,	O
hESC	O
derived	O
neural	O
cells	O
(	O
""""	O
NS	O
""""	O
,	O
n	O
=	O
3	O
)	O
,	O
and	O
differentiated	O
ES	O
cells	O
and	O
EB	O
,	O
(	O
""""	O
EB	O
""""	O
,	O
n	O
=	O
6	O
)	O
.	O

The	O
identified	O
biomarkers	O
can	O
be	O
used	O
to	O
distinguish	O
the	O
four	O
groups	O
of	O
cell	O
populations	O
.	O

Undifferentiated	O
hESCs	O
have	O
been	O
analyzed	O
by	O
EST	O
scan	O
,	O
MPSS	O
,	O
SAGE	O
and	O
microarray	O
[	O
5,10,16	O
]	O
.	O

The	O
goal	O
of	O
these	O
experiments	O
including	O
our	O
own	O
is	O
to	O
develop	O
a	O
low	O
cost	O
reliable	O
method	O
to	O
assess	O
multiple	O
samples	O
to	O
generate	O
a	O
global	O
database	O
of	O
markers	O
and	O
to	O
provide	O
a	O
method	O
of	O
identifying	O
core	O
measures	O
of	O
similarities	O
and	O
differences	O
across	O
multiple	O
laboratories	O
.	O

We	O
and	O
others	O
have	O
proposed	O
three	O
alternative	O
methods	O
of	O
assessment	O
:	O
Quantitative	O
RT	O
-	O
PCR	O
[	O
9,20	O
]	O
,	O
focused	O
arrays	O
[	O
27	O
]	O
or	O
a	O
large	O
scale	O
array	O
with	O
bioinformatics	O
tools	O
being	O
utilized	O
to	O
focus	O
on	O
appropriate	O
subsets	O
of	O
genes	O
[	O
5,7,15,16,28	O
]	O
.	O

Each	O
of	O
these	O
methods	O
has	O
its	O
advantages	O
and	O
disadvantages	O
.	O

The	O
present	O
results	O
suggest	O
that	O
the	O
global	O
Illumina	O
bead	O
array	O
retains	O
the	O
advantages	O
of	O
low	O
cost	O
per	O
sample	O
associated	O
with	O
focused	O
arrays	O
yet	O
still	O
has	O
the	O
strength	O
of	O
the	O
global	O
attributes	O
of	O
MPSS	O
or	O
EST	O
scan	O
while	O
requiring	O
much	O
less	O
RNA	O
and	O
turnaround	O
time	O
.	O

To	O
test	O
this	O
array	O
format	O
we	O
examined	O
samples	O
from	O
a	O
variety	O
of	O
laboratories	O
in	O
a	O
blinded	O
fashion	O
to	O
determine	O
whether	O
the	O
array	O
was	O
sufficiently	O
sensitive	O
and	O
rapid	O
for	O
routine	O
assessment	O
.	O

Duplicates	O
using	O
100	O
ng	O
of	O
RNA	O
were	O
run	O
and	O
results	O
obtained	O
forty	O
-	O
eight	O
hours	O
later	O
.	O

The	O
resolution	O
was	O
sufficient	O
that	O
ESC	O
samples	O
could	O
be	O
distinguished	O
from	O
one	O
another	O
and	O
a	O
variant	O
karyotypically	O
abnormal	O
subclone	O
could	O
be	O
distinguished	O
from	O
the	O
parent	O
population	O
(	O
correlation	O
coefficient	O
=	O
0.9043	O
)	O
.	O

Aliquots	O
of	O
the	O
pooled	O
ES	O
and	O
pooled	O
EB	O
samples	O
,	O
which	O
we	O
had	O
prepared	O
for	O
MPSS	O
,	O
were	O
included	O
in	O
this	O
run	O
to	O
compare	O
these	O
two	O
methods	O
directly	O
.	O

The	O
current	O
analysis	O
confirms	O
that	O
comparison	O
across	O
platforms	O
is	O
difficult	O
and	O
that	O
only	O
positive	O
results	O
can	O
be	O
treated	O
with	O
any	O
reliability	O
.	O

The	O
absence	O
of	O
expression	O
can	O
not	O
be	O
readily	O
interpreted	O
.	O

In	O
particular	O
,	O
genes	O
expressed	O
at	O
low	O
levels	O
(	O
greater	O
than	O
70	O
%	O
of	O
all	O
genes	O
detected	O
)	O
should	O
not	O
be	O
assessed	O
in	O
cross	O
platform	O
comparisons	O
.	O

The	O
limited	O
concordance	O
at	O
low	O
levels	O
raises	O
a	O
question	O
as	O
to	O
how	O
many	O
genes	O
are	O
actually	O
expressed	O
by	O
any	O
one	O
cell	O
line	O
and	O
whether	O
the	O
cutoff	O
of	O
3	O
tpm	O
used	O
for	O
MPSS	O
or	O
100	O
intensity	O
units	O
for	O
bead	O
arrays	O
is	O
a	O
reasonable	O
cutoff	O
.	O

We	O
used	O
100	O
units	O
for	O
our	O
analysis	O
and	O
we	O
would	O
suggest	O
that	O
readers	O
exercise	O
similar	O
caution	O
.	O

Nevertheless	O
even	O
at	O
this	O
higher	O
cutoff	O
the	O
arrays	O
were	O
remarkably	O
sensitive	O
and	O
allowed	O
us	O
to	O
readily	O
distinguish	O
between	O
samples	O
including	O
cells	O
grown	O
in	O
the	O
same	O
laboratory	O
.	O

The	O
basis	O
of	O
the	O
sensitivity	O
could	O
be	O
attributed	O
to	O
a	O
limited	O
set	O
of	O
genes	O
and	O
those	O
genes	O
could	O
be	O
identified	O
for	O
future	O
use	O
.	O

For	O
example	O
BG01V	O
,	O
while	O
much	O
more	O
similar	O
to	O
BG01	O
than	O
to	O
any	O
other	O
cell	O
type	O
,	O
could	O
still	O
be	O
distinguished	O
from	O
a	O
biological	O
replicate	O
of	O
BG01	O
by	O
the	O
expression	O
of	O
a	O
particular	O
subset	O
of	O
differentiation	O
markers	O
(	O
Figure	O
6	O
)	O
.	O

EC	O
cells	O
such	O
as	O
NTera2	O
could	O
be	O
distinguished	O
from	O
hESCs	O
by	O
the	O
expression	O
of	O
germ	O
cell	O
markers	O
and	O
the	O
presence	O
of	O
a	O
partially	O
inactivated	O
TGFβ	B
(	O
BMP	B
)	O
signaling	O
pathway	O
(	O
Figure	O
6	O
)	O
.	O

Distinguishing	O
ESCs	O
from	O
EBs	O
was	O
relatively	O
straightforward	O
.	O

We	O
have	O
confirmed	O
the	O
utility	O
of	O
previously	O
identified	O
markers	O
for	O
use	O
in	O
this	O
platform	O
as	O
well	O
as	O
identified	O
an	O
additional	O
set	O
of	O
markers	O
that	O
can	O
serve	O
as	O
biomarkers	O
to	O
distinguish	O
between	O
the	O
hESC	O
and	O
EB	O
states	O
.	O

A	O
subset	O
of	O
these	O
markers	O
have	O
been	O
used	O
to	O
develop	O
a	O
qPCR	O
assay	O
that	O
shows	O
such	O
a	O
high	O
sensitivity	O
that	O
changes	O
in	O
cell	O
behavior	O
can	O
be	O
detected	O
after	O
as	O
little	O
as	O
twenty	O
-	O
four	O
hours	O
and	O
the	O
development	O
of	O
EBs	O
can	O
be	O
reliably	O
staged	O
[	O
10,20	O
]	O
.	O

During	O
the	O
identification	O
of	O
ES	O
and	O
EB	O
specific	O
markers	O
,	O
we	O
have	O
noticed	O
that	O
some	O
known	O
hESC	O
markers	O
,	O
such	O
as	O
Nanog	B
,	O
was	O
not	O
detected	O
in	O
all	O
populations	O
of	O
hESCs	O
that	O
were	O
included	O
in	O
this	O
analysis	O
.	O

Several	O
ESC	O
-	O
specific	O
gene	O
,	O
including	O
Lin41	B
,	O
Sox2	B
and	O
FoxD3	B
,	O
were	O
not	O
detected	O
in	O
the	O
array	O
either	O
(	O
Table	O
3	O
)	O
.	O

We	O
believe	O
that	O
the	O
problem	O
with	O
Lin	B
41	I
,	O
Sox2	B
and	O
FoxD3	B
is	O
a	O
technical	O
one	O
as	O
we	O
were	O
able	O
to	O
confirm	O
expression	O
using	O
alternate	O
methods	O
.	O

We	O
are	O
in	O
progress	O
of	O
redesigning	O
appropriate	O
probes	O
for	O
these	O
genes	O
.	O

In	O
the	O
case	O
of	O
the	O
gene	O
Nanog	B
,	O
there	O
are	O
several	O
pseudo	O
genes	O
in	O
the	O
genome	O
for	O
Nanog	B
and	O
it	O
has	O
been	O
a	O
major	O
technical	O
challenge	O
designing	O
primers	O
or	O
probes	O
that	O
are	O
specific	O
and	O
sensitive	O
.	O

We	O
believe	O
that	O
a	O
partial	O
explanation	O
for	O
the	O
variability	O
in	O
Nanog	B
expression	O
is	O
due	O
to	O
the	O
lack	O
of	O
sensitivity	O
to	O
this	O
gene	O
.	O

However	O
,	O
immunocytochemistry	O
while	O
not	O
strictly	O
quantitative	O
shows	O
similar	O
variability	O
when	O
used	O
to	O
assess	O
Nanog	B
expression	O
in	O
different	O
cell	O
lines	O
[	O
9,27,28	O
]	O
.	O

This	O
large	O
comparison	O
between	O
samples	O
allowed	O
us	O
to	O
identify	O
markers	O
that	O
distinguish	O
human	O
feeder	O
cells	O
from	O
hESC	O
.	O

While	O
we	O
have	O
listed	O
19	O
potential	O
markers	O
(	O
Figure	O
3	O
)	O
and	O
identified	O
several	O
hundred	O
potential	O
markers	O
as	O
shown	O
in	O
Additional	O
file	O
5	O
,	O
we	O
suggest	O
that	O
as	O
few	O
as	O
3–4	O
genes	O
may	O
be	O
sufficient	O
.	O

Previously	O
we	O
found	O
that	O
as	O
few	O
as	O
four	O
were	O
satisfactory	O
to	O
distinguish	O
between	O
hESCs	O
and	O
hEBs	O
,	O
which	O
are	O
two	O
much	O
more	O
closely	O
related	O
samples	O
[	O
9	O
]	O
.	O

In	O
this	O
study	O
we	O
have	O
confirmed	O
by	O
qPCR	O
the	O
differential	O
expression	O
of	O
four	O
genes	O
,	O
THBS1	B
,	O
MMP3	B
,	O
TNFRSF11B	B
and	O
KRTH4	B
,	O
to	O
separate	O
human	O
fibroblast	O
feeders	O
and	O
hESCs	O
(	O
Figure	O
3	O
)	O
.	O

Several	O
markers	O
such	O
as	O
MMP3	B
and	O
TNFRSF11B	B
have	O
commercially	O
available	O
antibodies	O
(	O
R&D	O
systems	O
)	O
that	O
may	O
be	O
used	O
to	O
further	O
confirm	O
contamination	O
of	O
feeder	O
cells	O
by	O
immunocytochemistry	O
.	O

Efforts	O
to	O
identify	O
other	O
useful	O
antibodies	O
based	O
on	O
these	O
results	O
continue	O
[	O
29	O
]	O
.	O

While	O
we	O
have	O
focused	O
on	O
the	O
immediate	O
utility	O
of	O
the	O
Illumina	O
array	O
platform	O
,	O
it	O
is	O
important	O
to	O
remember	O
that	O
this	O
array	O
provides	O
a	O
global	O
snapshot	O
of	O
cell	O
state	O
and	O
the	O
data	O
obtained	O
can	O
be	O
readily	O
compared	O
in	O
order	O
to	O
determine	O
key	O
signaling	O
pathways	O
.	O

The	O
ability	O
to	O
compare	O
multiple	O
samples	O
in	O
one	O
run	O
enhances	O
data	O
selectivity	O
and	O
reliability	O
.	O

To	O
make	O
such	O
analysis	O
more	O
readily	O
available	O
,	O
we	O
utilized	O
several	O
software	O
tools	O
including	O
the	O
software	O
package	O
available	O
through	O
Illumina	O
.	O

The	O
BeadStudio	O
software	O
provided	O
with	O
the	O
BeadLab	O
and	O
BeadStudio	O
genetic	O
analysis	O
systems	O
for	O
use	O
with	O
the	O
bead	O
array	O
datasets	O
provides	O
a	O
useful	O
set	O
of	O
analytical	O
and	O
presentation	O
tools	O
that	O
allow	O
straightforward	O
comparisons	O
,	O
which	O
are	O
sufficient	O
for	O
average	O
users	O
.	O

For	O
detailed	O
analysis	O
we	O
recommend	O
using	O
more	O
specific	O
commercial	O
tools	O
or	O
software	O
packages	O
developed	O
by	O
NCBI	O
.	O

In	O
summary	O
,	O
the	O
Illumina	O
bead	O
array	O
has	O
several	O
key	O
strengths	O
including	O
high	O
throughput	O
,	O
low	O
cost	O
and	O
high	O
sensitivity	O
.	O

By	O
using	O
this	O
array	O
,	O
we	O
can	O
readily	O
detect	O
contaminating	O
feeders	O
and	O
spontaneous	O
differentiation	O
,	O
differentiate	O
male	O
and	O
female	O
lines	O
and	O
distinguish	O
between	O
one	O
undifferentiated	O
population	O
and	O
another	O
.	O

Such	O
a	O
global	O
analysis	O
allows	O
us	O
to	O
assess	O
context	O
dependent	O
signaling	O
and	O
identify	O
biomarkers	O
of	O
particular	O
states	O
of	O
cells	O
.	O

Our	O
future	O
efforts	O
will	O
focus	O
on	O
data	O
mining	O
and	O
developing	O
better	O
cross	O
platform	O
comparison	O
tools	O
and	O
generating	O
focused	O
high	O
throughput	O
arrays	O
for	O
quality	O
control	O
in	O
clinical	O
and	O
research	O
settings	O
.	O

hESC	O
cultureThe	O
hESC	O
lines	O
H1	O
,	O
H7	O
and	O
H9	O
(	O
WiCell	O
,	O
Madison	O
,	O
WI	O
)	O
were	O
cultured	O
on	O
feeder	O
layers	O
derived	O
from	O
mitotically	O
inactivated	O
HS27	O
human	O
fibroblast	O
cells	O
(	O
HS27	O
,	O
ATCC	O
)	O
,	O
or	O
mouse	O
embryonic	O
fibroblsts	O
or	O
under	O
feeder	O
-	O
free	O
conditions	O
on	O
Matrigel	O
(	O
BD	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
)	O
coated	O
plates	O
for	O
at	O
least	O
10	O
passages	O
.	O

Culture	O
medium	O
for	O
all	O
cultures	O
was	O
composed	O
of	O
DMEM	O
/	O
F12-Glutamax	O
1:1	O
,	O
20	O
%	O
Knockout	O
Serum	O
Replacement	O
,	O
2	O
mM	O
nonessential	O
amino	O
acids	O
,	O
100	O
μM	O
beta	O
-	O
mercaptoethanol	O
,	O
50	O
μg	O
/	O
ml	O
Pen	O
-	O
Strep	O
(	O
all	O
from	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
,	O
and	O
4	O
ng	O
/	O
ml	O
human	O
recombinant	O
basic	B
fibroblast	I
growth	I
factor	I
(	O
bFGF	B
/	O
FGF2	B
;	O
PeproTech	O
Inc.	O
,	O
Rocky	O
Hill	O
,	O
NJ	O
.	O
)	O

Feeder	O
-	O
free	O
cultures	O
were	O
prepared	O
for	O
gene	O
expression	O
analysis	O
by	O
manually	O
harvesting	O
individual	O
colonies	O
with	O
uniform	O
typical	O
undifferentiated	O
ESC	O
morphology	O
.	O

BG01	O
(	O
46	O
,	O
XY	O
)	O
,	O
BG02	O
(	O
46	O
,	O
XY	O
)	O
,	O
BG03	O
(	O
46	O
,	O
XX	O
)	O
,	O
I6	O
(	O
46	O
,	O
XY	O
)	O
and	O
BG01V	O
(	O
BG01	O
karyotypic	O
variant	O
:	O
49	O
,	O
XXY	O
,	O
+	O
12	O
,	O
+	O
17	O
)	O
:	O
Cells	O
were	O
maintained	O
for	O
3	O
(	O
BG01V	O
)	O
,	O
7	O
(	O
BG02	O
)	O
,	O
8	O
(	O
BG01	O
)	O
,	O
or	O
21	O
(	O
BG03	O
)	O
passages	O
under	O
feeder	O
-	O
free	O
condition	O
on	O
fibronectin	B
-	O
coated	O
plates	O
in	O
medium	O
that	O
had	O
been	O
conditioned	O
by	O
mouse	O
embryonic	O
fibroblasts	O
for	O
24	O
hours	O
.	O

Culture	O
medium	O
was	O
DMEM	O
/	O
F12	O
,	O
1:1	O
supplemented	O
with	O
20	O
%	O
Knockout	O
Serum	O
Replacement	O
,	O
2	O
mM	O
non	O
-	O
essential	O
amino	O
acids	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
50	O
μg	O
/	O
ml	O
Pen	O
-	O
Strep	O
,	O
100	O
μM	O
beta	O
-	O
mercaptoethanol	O
,	O
and	O
4	O
ng	O
/	O
ml	O
of	O
bFGF.Different	B
hESC	O
lines	O
were	O
grown	O
in	O
slightly	O
different	O
culture	O
conditions	O
as	O
described	O
above	O
.	O

H	O
lines	O
were	O
grown	O
on	O
Matrigel	O
coated	O
dishes	O
,	O
while	O
BG	O
lines	O
on	O
fibronectin	B
treated	O
dishes	O
.	O

These	O
coating	O
substrata	O
supported	O
the	O
growth	O
of	O
hESCs	O
similarly	O
,	O
as	O
evaluated	O
by	O
colony	O
morphology	O
,	O
immunocytochemistry	O
and	O
proliferation	O
rate	O
(	O
data	O
not	O
shown	O
)	O
.Embryoid	O
bodies	O
(	O
EBs	O
)	O
were	O
prepared	O
from	O
BG	O
lines	O
as	O
described	O
in	O
[	O
5	O
]	O
.	O

Cells	O
were	O
aggregated	O
and	O
cultured	O
on	O
non	O
-	O
adherent	O
substrata	O
for	O
fourteen	O
days	O
.	O

Other	O
cellsNTera2	O
cells	O
were	O
purchased	O
from	O
ATCC	O
and	O
cultured	O
in	O
parallel	O
with	O
hESCssamples	O
using	O
protocols	O
described	O
previously	O
[	O
21	O
]	O
.	O

HS27	O
embryonic	O
human	O
newborn	O
foreskin	O
cells	O
(	O
ATCC	O
CRL-1634	O
)	O
were	O
grown	O
in	O
DMEM	O
with	O
10%FBS.All	O
samples	O
included	O
in	O
this	O
study	O
can	O
be	O
found	O
in	O
Additional	O
file	O
6.Bead	O
array	O
gene	O
expression	O
analysisRNA	O
was	O
isolated	O
from	O
cultured	O
cells	O
using	O
the	O
Qiagen	O
RNEasy	O
kit	O
(	O
Qiagen	O
,	O
Inc	O
,	O
Valencia	O
,	O
CA	O
)	O
.	O

Sample	O
amplification	O
was	O
performed	O
using	O
100	O
ng	O
of	O
total	O
RNA	O
as	O
input	O
material	O
by	O
the	O
method	O
of	O
Van	O
Gelder	O
et	O
al	O
[	O
30	O
]	O
.	O

Amplified	O
RNA	O
synthesized	O
from	O
limited	O
quantities	O
of	O
heterogenous	O
cDNA	O
[	O
30	O
]	O
was	O
performed	O
using	O
the	O
Illumina	O
RNA	O
Amplification	O
kit	O
(	O
Ambion	O
,	O
Inc.	O
,	O
Austin	O
,	O
TX	O
)	O
following	O
the	O
Manufacturer	O
instructions	O
.	O

Labeling	O
was	O
achieved	O
by	O
use	O
of	O
the	O
incorporation	O
of	O
biotin-16-UTP	B
(	O
Perkin	O
Elmer	O
Life	O
and	O
Analytical	O
Sciences	O
,	O
Boston	O
,	O
MA	O
)	O
present	O
at	O
a	O
ratio	O
of	O
1:1	O
with	O
unlabeled	O
UTP	B
.	O

Labeled	O
,	O
amplified	O
material	O
(	O
700	O
ng	O
per	O
array	O
)	O
was	O
hybridized	O
to	O
a	O
pilot	O
version	O
of	O
the	O
Illumina	O
HumanRef-8	O
BeadChip	O
according	O
to	O
the	O
Manufacturer	O
's	O
instructions	O
(	O
Illumina	O
,	O
Inc.	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Amersham	O
fluorolink	O
streptavidin	B
-	O
Cy3	O
(	O
GE	O
Healthcare	O
Bio	O
-	O
Sciences	O
,	O
Little	O
Chalfont	O
,	O
UK	O
)	O
following	O
the	O
BeadChip	O
manual	O
.	O

Arrays	O
were	O
scanned	O
with	O
an	O
Illumina	O
Bead	O
array	O
Reader	O
confocal	O
scanner	O
according	O
to	O
the	O
Manufacturer	O
's	O
instructions	O
.	O

Array	O
data	O
processing	O
and	O
analysis	O
was	O
performed	O
using	O
Illumina	O
BeadStudio	O
software	O
.	O

Identification	O
of	O
differentially	O
expressed	O
genes	O
and	O
clustering	O
analysisDifferentially	O
expressed	O
genes	O
between	O
ES	O
and	O
EB	O
were	O
identified	O
by	O
ANOVA	O
at	O
p	O
value	O
0.05	O
using	O
bioconductor	O
[	O
17	O
]	O
.	O

Unsupervised	O
hierarchical	O
clustering	O
analysis	O
and	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
were	O
conducted	O
using	O
software	O
Pcluster	O
[	O
31	O
]	O
and	O
TreeView	O
[	O
18	O
]	O
.Identification	O
of	O
diagnostic	O
markersPAM	O
(	O
prediction	O
analysis	O
of	O
microarray	O
)	O
was	O
employed	O
for	O
the	O
identification	O
of	O
diagnostic	O
markers	O
from	O
insulin	B
pathway	O
genes	O
by	O
using	O
the	O
software	O
package	O
bioconductor	O
[	O
17	O
]	O
.	O

PAM	O
is	O
a	O
class	O
prediction	O
method	O
for	O
expression	O
data	O
mining	O
.	O

It	O
can	O
provide	O
a	O
list	O
of	O
significant	O
genes	O
whose	O
expression	O
characterizes	O
each	O
diagnostic	O
class	O
.	O

The	O
average	O
gene	O
expression	O
level	O
in	O
multiple	O
classes	O
,	O
such	O
as	O
ES	O
,	O
EB	O
,	O
NS	O
,	O
and	O
FB	O
,	O
was	O
divided	O
by	O
the	O
within	O
-	O
class	O
standard	O
deviation	O
for	O
that	O
gene	O
.	O

The	O
nearest	O
centroid	O
classification	O
computed	O
by	O
PAM	O
takes	O
the	O
protein	O
expression	O
profile	O
from	O
a	O
new	O
sample	O
,	O
and	O
compares	O
it	O
to	O
each	O
of	O
these	O
class	O
centroids	O
[	O
26	O
]	O
.RT	O
-	O
PCR	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
analysisTotal	O
RNA	O
was	O
isolated	O
with	O
TRIzol	O
(	O
Invitrogen	O
.	O

cDNA	O
was	O
synthesized	O
using	O
2.5	O
μg	O
total	O
RNA	O
in	O
a	O
20-μl	O
reaction	O
with	O
Superscript	O
II	O
(	O
Invitrogen	O
)	O
and	O
oligo	O
(	O
dT	O
)	O
12–18	O
(	O
Promega	O
;	O
Madison	O
,	O
WI	O
)	O
.	O

One	O
microliter	O
RNase	B
H	I
(	O
Invitrogen	O
)	O
was	O
added	O
to	O
each	O
tube	O
and	O
incubated	O
for	O
20	O
minutes	O
at	O
37	O
°	O
C	O
before	O
proceeding	O
to	O
the	O
RT	O
-	O
PCR	O
analysis	O
.	O

The	O
PCR	O
primers	O
are	O
:	O
RPS4Y	B
-	O
forward	O
:	O
5	O
'	O
AGATTCTCTTCCGTCGCAG	O
3	O
'	O
,	O
RPS4Y	B
-	O
reverse	O
,	O
5	O
'	O
CTCCACCAATCACCATACAC	O
3	O
'	O
;	O
EIFAY	B
-	O
forward	O
,	O
5	O
'	O
CTGCTGCATCTTAGTTCAGTC	O
3	O
'	O
;	O
EIFAY	B
-	O
reverse	O
5	O
'	O
CTTCCAATCGTCCATTTCCC	O
3	O
'	O
.	O

Quantitative	O
real	O
time	O
PCR	O
gene	O
specific	O
primer	O
pairs	O
and	O
probes	O
were	O
purchased	O
from	O
Applied	O
Biosystems	O
(	O
Foster	O
City	O
,	O
CA	O
)	O
for	O
the	O
following	O
genes	O
:	O
MMP3	B
(	O
Hs00233962_m1	O
)	O
,	O
TFRSF11B	B
(	O
Hs00171068_m1	O
)	O
,	O
THBS1	B
(	O
Hs00170236_m1	O
)	O
,	O
KRTHA4	B
(	O
Hs00606019_gH	O
)	O
,	O
and	O
for	O
internal	O
control	O
β	B
-	I
actin	I
(	O
ACTB	B
,	O
Hs99999903_m1	O
)	O
.	O

BackgroundHuman	O
stem	O
cells	O
are	O
viewed	O
as	O
a	O
possible	O
source	O
of	O
neurons	O
for	O
a	O
cell	O
-	O
based	O
therapy	O
of	O
neurodegenerative	O
disorders	O
,	O
such	O
as	O
Parkinson	O
's	O
disease	O
.	O

Several	O
protocols	O
that	O
generate	O
different	O
types	O
of	O
neurons	O
from	O
human	O
stem	O
cells	O
(	O
hSCs	O
)	O
have	O
been	O
developed	O
.	O

Nevertheless	O
,	O
the	O
cellular	O
mechanisms	O
that	O
underlie	O
the	O
development	O
of	O
neurons	O
in	O
vitro	O
as	O
they	O
are	O
subjected	O
to	O
the	O
specific	O
differentiation	O
protocols	O
are	O
often	O
poorly	O
understood	O
.	O

ResultsWe	O
have	O
designed	O
a	O
focused	O
DNA	O
(	O
oligonucleotide	O
-	O
based	O
)	O
large	O
-	O
scale	O
microarray	O
platform	O
(	O
named	O
""""	O
NeuroStem	O
Chip	O
""""	O
)	O
and	O
used	O
it	O
to	O
study	O
gene	O
expression	O
patterns	O
in	O
hSCs	O
as	O
they	O
differentiate	O
into	O
neurons	O
.	O

We	O
have	O
selected	O
genes	O
that	O
are	O
relevant	O
to	O
cells	O
(	O
i	O
)	O
being	O
stem	O
cells	O
,	O
(	O
ii	O
)	O
becoming	O
neurons	O
,	O
and	O
(	O
iii	O
)	O
being	O
neurons	O
.	O

The	O
NeuroStem	O
Chip	O
has	O
over	O
1,300	O
pre	O
-	O
selected	O
gene	O
targets	O
and	O
multiple	O
controls	O
spotted	O
in	O
quadruplicates	O
(	O
~46,000	O
spots	O
total	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
the	O
NeuroStem	O
Chip	O
in	O
detail	O
and	O
describe	O
the	O
special	O
advantages	O
it	O
offers	O
to	O
the	O
fields	O
of	O
experimental	O
neurology	O
and	O
stem	O
cell	O
biology	O
.	O

To	O
illustrate	O
the	O
utility	O
of	O
NeuroStem	O
Chip	O
platform	O
,	O
we	O
have	O
characterized	O
an	O
undifferentiated	O
population	O
of	O
pluripotent	O
human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
,	O
cell	O
line	O
SA02	O
)	O
.	O

In	O
addition	O
,	O
we	O
have	O
performed	O
a	O
comparative	O
gene	O
expression	O
analysis	O
of	O
those	O
cells	O
versus	O
a	O
heterogeneous	O
population	O
of	O
hESC	O
-	O
derived	O
cells	O
committed	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
PA6	O
stromal	O
cells	O
for	O
16	O
days	O
and	O
containing	O
a	O
few	O
tyrosine	B
hydroxylase	I
-	O
positive	O
dopaminergic	O
neurons	O
.	O

ConclusionWe	O
characterized	O
the	O
gene	O
expression	O
profiles	O
of	O
undifferentiated	O
and	O
dopaminergic	O
lineage	O
-	O
committed	O
hESC	O
-	O
derived	O
cells	O
using	O
a	O
highly	O
focused	O
custom	O
microarray	O
platform	O
(	O
NeuroStem	O
Chip	O
)	O
that	O
can	O
become	O
an	O
important	O
research	O
tool	O
in	O
human	O
stem	O
cell	O
biology	O
.	O

We	O
propose	O
that	O
the	O
areas	O
of	O
application	O
for	O
NeuroStem	O
microarray	O
platform	O
could	O
be	O
the	O
following	O
:	O
(	O
i	O
)	O
characterization	O
of	O
the	O
expression	O
of	O
established	O
,	O
pre	O
-	O
selected	O
gene	O
targets	O
in	O
hSC	O
lines	O
,	O
including	O
newly	O
derived	O
ones	O
,	O
(	O
ii	O
)	O
longitudinal	O
quality	O
control	O
for	O
maintained	O
hSC	O
populations	O
,	O
(	O
iii	O
)	O
following	O
gene	O
expression	O
changes	O
during	O
differentiation	O
under	O
defined	O
cell	O
culture	O
conditions	O
,	O
and	O
(	O
iv	O
)	O
confirming	O
the	O
success	O
of	O
differentiation	O
into	O
specific	O
neuronal	O
subtypes	O
.	O

Modern	O
DNA	O
microarrays	O
permit	O
a	O
comprehensive	O
analysis	O
of	O
quantitative	O
and	O
qualitative	O
changes	O
in	O
RNA	O
transcript	O
abundance	O
,	O
outlining	O
the	O
cross	O
-	O
sections	O
of	O
gene	O
expression	O
and	O
alterations	O
of	O
these	O
in	O
response	O
to	O
genetic	O
or	O
environmental	O
stimuli	O
.	O

Genome	O
-	O
scale	O
microarrays	O
(	O
cDNA-	O
or	O
oligonucleotide	O
-	O
based	O
)	O
are	O
most	O
valuable	O
when	O
screening	O
populations	O
of	O
cells	O
for	O
the	O
novel	O
genes	O
reflecting	O
potential	O
diagnostic	O
and	O
prognostic	O
markers	O
or	O
for	O
an	O
identification	O
of	O
novel	O
therapeutic	O
targets	O
.	O

On	O
the	O
other	O
hand	O
,	O
custom	O
microarray	O
platforms	O
that	O
focus	O
on	O
specific	O
pre	O
-	O
selected	O
subset	O
of	O
genes	O
relevant	O
to	O
a	O
particular	O
field	O
of	O
investigation	O
can	O
be	O
less	O
costly	O
and	O
more	O
suitable	O
for	O
detection	O
of	O
smaller	O
gene	O
expression	O
changes	O
.	O

Microarray	O
technology	O
has	O
added	O
important	O
information	O
on	O
both	O
normal	O
development	O
and	O
pathological	O
changes	O
in	O
neurons	O
.	O

This	O
is	O
well	O
illustrated	O
by	O
multiple	O
studies	O
on	O
substantia	O
nigra	O
dopaminergic	O
neurons	O
,	O
which	O
degenerate	O
in	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
[	O
1	O
-	O
5	O
]	O
.	O

The	O
shortcomings	O
of	O
pharmacological	O
therapies	O
in	O
PD	O
have	O
stimulated	O
a	O
search	O
for	O
alternative	O
treatment	O
strategies	O
.	O

In	O
successful	O
cases	O
,	O
transplants	O
of	O
human	O
embryonic	O
mesencephalic	O
dopaminergic	O
neurons	O
can	O
both	O
restore	O
dopaminergic	O
neurotransmission	O
and	O
provide	O
some	O
symptomatic	O
relief	O
[	O
6	O
-	O
8	O
]	O
.	O

A	O
wider	O
application	O
of	O
neural	O
transplantation	O
in	O
PD	O
is	O
,	O
however	O
,	O
currently	O
not	O
feasible	O
due	O
to	O
the	O
unpredictable	O
and	O
variable	O
outcome	O
,	O
the	O
risks	O
of	O
unwanted	O
side	O
-	O
effects	O
(	O
dyskinesias	O
)	O
[	O
9,10	O
]	O
and	O
ethical	O
and	O
practical	O
problems	O
associated	O
with	O
using	O
donor	O
cells	O
obtained	O
from	O
aborted	O
embryos	O
and	O
fetuses	O
[	O
11,12	O
]	O
.	O

Human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
are	O
considered	O
a	O
promising	O
future	O
source	O
of	O
cells	O
for	O
cell	O
replacement	O
therapy	O
in	O
PD	O
and	O
other	O
neurological	O
conditions	O
[	O
13	O
]	O
.	O

They	O
could	O
constitute	O
a	O
virtually	O
infinite	O
source	O
of	O
self	O
-	O
renewing	O
cells	O
that	O
can	O
be	O
persuaded	O
to	O
differentiate	O
into	O
specific	O
types	O
of	O
neural	O
cells	O
,	O
including	O
dopaminergic	O
neurons	O
[	O
14	O
-	O
16	O
]	O
.	O

The	O
molecular	O
mechanisms	O
that	O
govern	O
development	O
of	O
cultured	O
hESCs	O
into	O
specific	O
types	O
of	O
neural	O
cells	O
are	O
not	O
fully	O
understood	O
.	O

To	O
promote	O
our	O
understanding	O
of	O
such	O
mechanisms	O
,	O
it	O
would	O
be	O
valuable	O
to	O
have	O
tools	O
that	O
readily	O
and	O
reproducibly	O
can	O
help	O
to	O
characterize	O
the	O
cells	O
as	O
they	O
differentiate	O
from	O
pluripotent	O
stem	O
cells	O
into	O
post	O
-	O
mitotic	O
neurons	O
.	O

This	O
important	O
issue	O
was	O
addressed	O
in	O
earlier	O
studies	O
by	O
Luo	O
et	O
al.	O
and	O
Yang	O
et	O
al.	O
,	O
who	O
designed	O
small	O
-	O
to	O
-	O
moderate	O
scale	O
custom	O
microarray	O
platforms	O
(	O
281	O
and	O
755	O
gene	O
targets	O
,	O
respectively	O
)	O
[	O
17,18	O
]	O
.	O

In	O
addition	O
SuperArray	O
Bioscience	O
Corporation	O
(	O
Frederick	O
,	O
MD	O
,	O
USA	O
)	O
have	O
manufactured	O
a	O
range	O
of	O
small	O
-	O
scale	O
arrays	O
(	O
263	O
gene	O
targets	O
for	O
human	O
array	O
;	O
[	O
19	O
]	O
)	O
.	O

We	O
sought	O
to	O
create	O
an	O
improved	O
and	O
updated	O
microarray	O
platform	O
for	O
hESC	O
/	O
neuronal	O
differentiation	O
-	O
oriented	O
gene	O
expression	O
studies	O
.	O

Therefore	O
,	O
we	O
generated	O
a	O
specialized	O
large	O
-	O
scale	O
DNA	O
microarray	O
platform	O
(	O
the	O
""""	O
NeuroStem	O
Chip	O
""""	O
)	O
that	O
has	O
over	O
1,300	O
pre	O
-	O
selected	O
gene	O
targets	O
and	O
multiple	O
controls	O
spotted	O
in	O
quadruplicates	O
(	O
~46,000	O
spots	O
total	O
)	O
.	O

Here	O
we	O
introduce	O
the	O
platform	O
and	O
the	O
advantages	O
it	O
can	O
offers	O
to	O
neuroscientists	O
and	O
stem	O
cell	O
biologists	O
:	O
particularly	O
,	O
in	O
the	O
niche	O
of	O
gene	O
expression	O
-	O
oriented	O
characterization	O
of	O
the	O
samples	O
using	O
an	O
assay	O
of	O
pre	O
-	O
selected	O
,	O
already	O
established	O
gene	O
targets	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
use	O
the	O
NeuroStem	O
Chip	O
to	O
characterize	O
an	O
undifferentiated	O
population	O
of	O
pluripotent	O
hESCs	O
(	O
cell	O
line	O
SA02	O
,	O
Cellartis	O
AB	O
,	O
Göteborg	O
,	O
Sweden	O
)	O
and	O
compare	O
the	O
gene	O
expression	O
in	O
those	O
cells	O
with	O
that	O
of	O
a	O
hESC	O
-	O
derived	O
cell	O
population	O
rich	O
in	O
neurons	O
,	O
including	O
tyrosine	B
hydroxylase	I
-	O
positive	O
dopaminergic	O
neurons	O
.	O

Stem	O
cells	O
have	O
unique	O
biological	O
characteristics	O
,	O
but	O
only	O
a	O
limited	O
number	O
of	O
genes	O
are	O
currently	O
recognized	O
as	O
established	O
stem	O
cell	O
markers	O
.	O

Examples	O
include	O
POU	B
domain	I
,	I
class	I
5	I
,	I
transcription	I
factor	I
1	I
(	O
Oct3	B
/	I
4	I
)	O
,	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
(	O
Stat3	B
)	O
,	O
teratocarcinoma	B
-	I
derived	I
growth	I
factor	I
(	O
Tdgf1	B
)	O
,	O
Enk	B
-	I
pending	I
(	O
Nanog	B
)	O
,	O
undifferentiated	B
embryonic	I
cell	I
transcription	I
factor	I
1	I
(	O
Utf1	B
)	O
and	O
DNA	B
methyltransferase	I
3B	I
(	O
Dnmt3b	B
)	O
[	O
20	O
]	O
.	O

At	O
the	O
same	O
time	O
,	O
hundreds	O
of	O
genes	O
are	O
suggested	O
as	O
candidate	O
markers	O
for	O
""""	O
stemness	O
""""	O
,	O
but	O
their	O
coupling	O
to	O
the	O
undifferentiated	O
stem	O
cell	O
state	O
is	O
not	O
yet	O
fully	O
verified	O
[	O
21	O
]	O
.	O

The	O
concept	O
of	O
""""	O
stemness	O
""""	O
(	O
term	O
introduced	O
in	O
1986	O
by	O
Grossman	O
&	O
Levine	O
)	O
is	O
defined	O
as	O
""""	O
core	O
stem	O
cell	O
properties	O
that	O
underlie	O
self	O
-	O
renewal	O
and	O
the	O
ability	O
to	O
generate	O
differentiated	O
progeny	O
""""	O
[	O
22	O
]	O
.	O

Considering	O
the	O
complexity	O
of	O
the	O
processes	O
involved	O
,	O
stemness	O
can	O
hardly	O
be	O
ensured	O
by	O
co	O
-	O
operation	O
of	O
just	O
a	O
few	O
genes	O
.	O

Nevertheless	O
,	O
three	O
stemness	O
genes	O
(	O
namely	O
,	O
Oct3	B
/	I
4	I
,	O
Stat3	B
and	O
Nanog	B
)	O
are	O
considered	O
""""	O
master	O
"""-"	O
genes	O
that	O
control	O
the	O
self	O
-	O
renewing	O
process	O
[	O
23,24	O
]	O
.	O

Various	O
types	O
of	O
stem	O
cells	O
,	O
such	O
as	O
hematopoietic	O
,	O
mesenchymal	O
and	O
neural	O
(	O
HSCs	O
,	O
MSCs	O
and	O
NSCs	O
,	O
respectively	O
)	O
,	O
embryonic	O
germ	O
and	O
embryonic	O
carcinoma	O
cells	O
(	O
EGCs	O
and	O
ECCs	O
,	O
respectively	O
)	O
are	O
all	O
characterized	O
by	O
variations	O
in	O
gene	O
expression	O
profiles	O
,	O
and	O
only	O
a	O
few	O
gene	O
markers	O
are	O
associated	O
with	O
all	O
these	O
cell	O
types	O
[	O
25,26	O
]	O
.	O

We	O
have	O
aimed	O
to	O
embrace	O
the	O
most	O
comprehensive	O
set	O
of	O
those	O
genes	O
into	O
a	O
solitary	O
array	O
,	O
the	O
NeuroStem	O
Chip	O
.	O

Thereby	O
,	O
it	O
is	O
possible	O
to	O
employ	O
it	O
to	O
monitor	O
the	O
relative	O
expression	O
levels	O
of	O
numerous	O
known	O
and	O
candidate	O
stemness	O
genes	O
in	O
a	O
single	O
experiment	O
.	O

Similar	O
to	O
the	O
genetic	O
bases	O
underlying	O
stemness	O
,	O
cell	O
differentiation	O
is	O
associated	O
with	O
altered	O
expression	O
levels	O
of	O
certain	O
recognized	O
or	O
candidate	O
genes	O
[	O
25	O
]	O
.	O

We	O
therefore	O
incorporated	O
gene	O
markers	O
of	O
development	O
and	O
differentiation	O
in	O
general	O
,	O
and	O
that	O
of	O
neuronal	O
and	O
dopaminergic	O
differentiation	O
in	O
particular	O
,	O
into	O
the	O
NeuroStem	O
Chip	O
.	O

Examples	O
include	O
markers	O
for	O
the	O
processes	O
of	O
neuronal	O
maturation	O
,	O
axonal	O
branching	O
,	O
neural	O
/	O
neuronal	O
survival	O
,	O
etc	O
.	O

Finally	O
,	O
we	O
ensured	O
that	O
known	O
markers	O
for	O
specific	O
types	O
of	O
neurons	O
,	O
allowing	O
identification	O
of	O
individual	O
cell	O
types	O
,	O
were	O
present	O
on	O
the	O
chip	O
.	O

We	O
paid	O
special	O
attention	O
to	O
genes	O
associated	O
with	O
the	O
differentiation	O
and	O
maturation	O
of	O
dopaminergic	O
neurons	O
.	O

In	O
many	O
published	O
studies	O
,	O
the	O
expression	O
of	O
only	O
a	O
single	O
(	O
tyrosine	B
hydroxylase	I
,	O
TH	B
)	O
or	O
2–3	O
markers	O
for	O
dopaminergic	O
neurons	O
(	O
e.g.	O
amino	B
acid	I
decarboxylase	I
(	O
AADC	B
)	O
,	O
dopamine	B
transporter	I
(	O
DAT	B
)	O
,	O
vesicular	B
monoamine	I
transporter	I
2	I
(	O
VMAT2	B
)	O
)	O
have	O
been	O
used	O
to	O
indicate	O
dopaminergic	O
identity	O
of	O
neurons	O
.	O

In	O
contrast	O
,	O
the	O
NeuroStem	O
Chip	O
includes	O
oligonucleotide	O
probes	O
for	O
88	O
genes	O
related	O
to	O
dopaminergic	O
neurons	O
,	O
thus	O
being	O
more	O
comprehensive	O
in	O
this	O
sense	O
,	O
compared	O
to	O
other	O
existing	O
microarray	O
platforms	O
,	O
including	O
focused	O
ones	O
[	O
17,18	O
]	O
.	O

Those	O
entries	O
encompass	O
recognized	O
and	O
candidate	O
markers	O
for	O
dopaminergic	O
neurons	O
(	O
mature	O
and	O
early	O
)	O
and	O
progenitors	O
,	O
as	O
well	O
as	O
markers	O
for	O
the	O
maturation	O
and	O
differentiation	O
of	O
the	O
latter	O
(	O
Table	O
1	O
)	O
.	O

Table	O
2	O
represents	O
conditional	O
functional	O
breakdown	O
of	O
genes	O
targeted	O
by	O
the	O
NeuroStem	O
microarray	O
platform	O
.	O

A	O
number	O
of	O
important	O
gene	O
groups	O
that	O
are	O
included	O
in	O
the	O
chip	O
are	O
not	O
mentioned	O
in	O
Table	O
2	O
.	O

Among	O
these	O
,	O
entries	O
related	O
to	O
Dickkopf	B
gene	O
family	O
,	O
galanin-	B
,	I
melatonin-	I
,	I
vasoactive	I
intestinal	I
peptide	I
(	O
VIP	B
)	O
-	O
,	O
cAMP	B
response	I
element	I
-	I
binding	I
protein	I
(	O
CREB	B
)	O
-	O
and	O
B	B
cell	I
leukemia	I
2	I
(	O
Bcl2	B
)	O
oncogene	O
-	O
related	O
are	O
present	O
.	O

Many	O
of	O
them	O
play	O
potentially	O
important	O
,	O
yet	O
undefined	O
,	O
roles	O
in	O
the	O
biology	O
of	O
stem	O
cells	O
.	O

Additionally	O
,	O
we	O
included	O
some	O
genes	O
implicated	O
in	O
disease	O
mechanisms	O
of	O
neurodegenerative	O
disorders	O
(	O
most	O
importantly	O
,	O
Parkinson	O
's	O
disease	O
and	O
Alzheimer	O
's	O
disease	O
)	O
in	O
the	O
chip	O
.	O

Furthermore	O
,	O
we	O
incorporated	O
a	O
number	O
of	O
markers	O
for	O
distinct	O
differentiation	O
pathways	O
(	O
e.g.	O
hematopoietic	O
and	O
pancreatic	O
)	O
and	O
cell	O
types	O
(	O
e.g.	O
cancer	O
subtypes	O
and	O
a	O
range	O
of	O
normal	O
cell	O
types	O
)	O
to	O
serve	O
as	O
essential	O
controls	O
.	O

Taken	O
together	O
,	O
we	O
believe	O
that	O
in	O
its	O
present	O
form	O
NeuroStem	O
Chip	O
represents	O
currently	O
most	O
comprehensive	O
gene	O
expression	O
platform	O
for	O
studies	O
on	O
stem	O
cells	O
,	O
neural	O
/	O
neuronal	O
differentiation	O
,	O
human	O
neurodegeneration	O
and	O
neuronal	O
survival	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
complete	O
layout	O
of	O
NeuroStem	O
Chip	O
will	O
be	O
disclosed	O
to	O
the	O
academic	O
community	O
,	O
upon	O
request	O
.	O

The	O
microarray	O
format	O
we	O
selected	O
relies	O
on	O
long	O
oligonucleotide	O
molecules	O
(	O
69–71	O
nucleotides	O
)	O
printed	O
over	O
a	O
solid	O
surface	O
.	O

We	O
spotted	O
the	O
synthesized	O
oligonucleotides	O
(	O
Operon	O
Biotechnologies	O
)	O
with	O
a	O
constant	O
concentration	O
across	O
the	O
slides	O
,	O
and	O
evaluated	O
the	O
quality	O
and	O
consistency	O
of	O
spotting	O
in	O
a	O
series	O
of	O
control	O
experiments	O
.	O

We	O
then	O
illustrated	O
the	O
utility	O
and	O
technical	O
reliability	O
of	O
the	O
NeuroStem	O
Chip	O
by	O
characterizing	O
the	O
gene	O
expression	O
profile	O
of	O
commonly	O
utilized	O
hESC	O
line	O
SA02	O
(	O
Sahlgrenska	O
2	O
;	O
[	O
27	O
]	O
)	O
,	O
including	O
(	O
i	O
)	O
undifferentiated	O
cells	O
and	O
(	O
ii	O
)	O
cells	O
committed	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
.	O

For	O
the	O
first	O
of	O
these	O
,	O
we	O
used	O
total	O
RNA	O
sample	O
purified	O
from	O
hESC	O
colonies	O
that	O
exhibited	O
morphology	O
consistent	O
with	O
cell	O
proliferation	O
and	O
the	O
absence	O
of	O
spontaneous	O
differentiation	O
(	O
Figure	O
1A	O
)	O
.	O

We	O
also	O
evaluated	O
the	O
expression	O
of	O
the	O
cell	O
cycle	O
marker	O
Ki67	B
and	O
the	O
pluripotency	O
marker	O
OCT3	B
/	I
4	I
in	O
the	O
sample	O
by	O
immunocytochemistry	O
(	O
Figure	O
1B	O
–	O
E	O
)	O
.	O

Co	O
-	O
culturing	O
of	O
ESCs	O
with	O
murine	O
stromal	O
cells	O
(	O
including	O
PA6	O
cell	O
line	O
)	O
rapidly	O
generates	O
dopaminergic	O
neurons	O
from	O
ESCs	O
by	O
an	O
unexplained	O
mechanism	O
termed	O
stromal	B
cell	I
-	I
derived	I
inducing	I
activity	I
(	O
SDIA	B
;	O
[	O
28,29	O
]	O
)	O
.	O

We	O
therefore	O
committed	O
hESCs	O
toward	O
the	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
PA6	O
cells	O
for	O
16	O
days	O
,	O
resulting	O
in	O
appearance	O
of	O
cells	O
positive	O
for	O
early	O
and	O
late	O
neuronal	O
markers	O
,	O
including	O
nestin	B
,	O
β	B
-	I
III	I
-	I
tubulin	I
,	O
and	O
TH	B
,	O
the	O
established	O
marker	O
of	O
dopaminergic	O
neurons	O
(	O
Figure	O
2	O
)	O
.	O

To	O
verify	O
the	O
expression	O
of	O
some	O
key	O
stem	O
cell-	O
and	O
neural	O
phenotype	O
-	O
associated	O
genes	O
we	O
performed	O
RT	O
-	O
PCR	O
comparing	O
RNA	O
samples	O
from	O
the	O
undifferentiated	O
hESCs	O
with	O
hESCs	O
of	O
the	O
same	O
line	O
differentiated	O
toward	O
neuronal	O
/	O
dopaminergic	O
pathway	O
,	O
as	O
described	O
above	O
.	O

The	O
expression	O
profile	O
outlined	O
by	O
RT	O
-	O
PCR	O
confirmed	O
the	O
identity	O
of	O
the	O
sample	O
used	O
(	O
Figure	O
3	O
)	O
.	O

After	O
performing	O
RNA	O
integrity	O
tests	O
,	O
we	O
incorporated	O
fluorescent	O
labels	O
to	O
the	O
amplified	O
RNA	O
samples	O
from	O
hESCs	O
(	O
Cyanine	O
3-CTP	O
(	O
Cy3	O
)	O
and	O
Cyanine	O
5-CTP	O
(	O
Cy5	O
)	O
)	O
,	O
hESC	O
-	O
derived	O
cells	O
containing	O
TH	B
-	O
positive	O
neurons	O
(	O
Cy3	O
and	O
Cy5	O
)	O
and	O
human	O
universal	O
reference	O
RNA	O
(	O
Cy5	O
)	O
,	O
and	O
hybridized	O
aliquots	O
with	O
NeuroStem	O
microarray	O
slides	O
using	O
the	O
following	O
conditions	O
:	O
hESC	O
vs.	O
reference	O
,	O
Cy3	O
:	O
Cy5	O
=	O
(	O
i	O
)	O
20:10	O
pmol	O
,	O
and	O
(	O
ii	O
)	O
10:5	O
pmol	O
;	O
and	O
hESC	O
vs.	O
hESC	O
-	O
derived	O
cells	O
,	O
Cy3	O
:	O
Cy5	O
=	O
(	O
iii	O
)	O
30:20	O
pmol	O
,	O
respectively	O
.	O

Universal	O
reference	O
RNA	O
has	O
been	O
previously	O
established	O
as	O
a	O
standard	O
reference	O
material	O
for	O
microarray	O
experiments	O
,	O
proving	O
an	O
ability	O
to	O
effectively	O
hybridize	O
to	O
a	O
large	O
fraction	O
of	O
microarray	O
spots	O
[	O
30	O
]	O
.	O

We	O
performed	O
two	O
-	O
color	O
hybridizations	O
(	O
e.g.	O
for	O
the	O
experiment	O
vs.	O
reference	O
)	O
following	O
an	O
established	O
protocol	O
[	O
31	O
]	O
,	O
and	O
included	O
dye	O
-	O
flip	O
technical	O
replicates	O
in	O
the	O
analysis	O
(	O
Figure	O
4	O
)	O
.	O

Using	O
the	O
online	O
software	O
program	O
BASE	O
[	O
32	O
]	O
we	O
sequentially	O
filtered	O
the	O
data	O
by	O
background	O
subtraction	O
,	O
negative	O
flagging	O
,	O
negative	O
intensities	O
and	O
for	O
inconsistent	O
data	O
amongst	O
replicates	O
[	O
33	O
]	O
.	O

Figure	O
5A	O
shows	O
a	O
comparison	O
of	O
the	O
spot	O
intensities	O
prior	O
to	O
normalization	O
(	O
M	O
versus	O
A	O
plot	O
)	O
,	O
with	O
the	O
Log2	O
of	O
the	O
expression	O
ratio	O
between	O
Cy3	O
/	O
Cy5	O
being	O
plotted	O
as	O
a	O
function	O
of	O
the	O
log10	O
of	O
the	O
mean	O
of	O
the	O
total	O
expression	O
intensities	O
for	O
Cy3	O
and	O
Cy5	O
channels	O
.	O

The	O
deviation	O
of	O
the	O
line	O
from	O
zero	O
revealed	O
a	O
need	O
for	O
normalization	O
,	O
so	O
prior	O
to	O
data	O
analyses	O
we	O
normalized	O
signals	O
using	O
a	O
locally	O
weighted	O
scatterplot	O
-	O
smoothing	O
regression	O
(	O
LOWESS	O
)	O
algorithm	O
(	O
Figure	O
5A	O
–	O
B	O
;	O
fitted	O
line	O
)	O
implemented	O
in	O
BASE	O
.	O

Since	O
the	O
reproducibility	O
of	O
two	O
-	O
color	O
microarray	O
gene	O
expression	O
data	O
is	O
critically	O
important	O
,	O
we	O
calculated	O
Pearson	O
correlation	O
coefficients	O
of	O
the	O
reporters	O
present	O
in	O
the	O
filtered	O
database	O
comparing	O
the	O
average	O
expression	O
ratios	O
(	O
7005	O
for	O
hESCs	O
vs.	O
universal	O
reference	O
;	O
6947	O
for	O
undifferentiated	O
vs.	O
neuronal	O
/	O
dopaminergic	O
lineage	O
-	O
committed	O
hESCs	O
)	O
.	O

Results	O
obtained	O
revealed	O
that	O
data	O
were	O
consistent	O
across	O
technical	O
replicates	O
(	O
dye	O
-	O
swap	O
and	O
amount	O
of	O
loaded	O
material	O
)	O
,	O
showing	O
general	O
high	O
reproducibility	O
:	O
e.g.	O
,	O
correlation	O
coefficients	O
were	O
greater	O
than	O
0.96	O
for	O
technical	O
replicates	O
and	O
0.78	O
for	O
dye	O
-	O
swapping	O
samples	O
in	O
hESCs	O
vs.	O
universal	O
reference	O
hybridizations	O
(	O
Table	O
3	O
)	O
.	O

To	O
detect	O
genes	O
with	O
high	O
expression	O
levels	O
in	O
hESC	O
samples	O
,	O
we	O
filtered	O
data	O
for	O
intensity	O
values	O
>	O
100	O
in	O
the	O
hESC	O
sample	O
and	O
performed	O
clustering	O
analysis	O
using	O
the	O
TIGR	O
MultiExperiment	O
Viewer	O
(	O
MEV	O
;	O
[	O
34	O
]	O
)	O
.	O

To	O
visualize	O
variations	O
of	O
spot	O
/	O
reporter	O
per	O
technical	O
replicate	O
,	O
hierarchical	O
clustering	O
was	O
performed	O
by	O
K	O
-	O
means	O
classifier	O
based	O
on	O
the	O
linear	O
-	O
correlation	O
-	O
based	O
distance	O
(	O
Pearson	O
,	O
centred	O
)	O
method	O
.	O

The	O
optimal	O
number	O
of	O
clusters	O
was	O
determined	O
empirically	O
to	O
produce	O
the	O
most	O
balanced	O
ratio	O
of	O
entries	O
to	O
cluster	O
of	O
highly	O
expressed	O
genes	O
.	O

A	O
cluster	O
of	O
101	O
genes	O
up	O
-	O
regulated	O
in	O
the	O
hESC	O
sample	O
[	O
see	O
Additional	O
file	O
1	O
]	O
,	O
was	O
plotted	O
in	O
a	O
centroid	O
graph	O
(	O
Figure	O
5C	O
)	O
;	O
the	O
variation	O
across	O
technical	O
replicates	O
was	O
low	O
.	O

We	O
merged	O
technical	O
replicates	O
to	O
generate	O
a	O
list	O
of	O
the	O
most	O
up	O
-	O
regulated	O
genes	O
expressed	O
in	O
the	O
hESC	O
sample	O
compared	O
to	O
the	O
universal	O
reference	O
RNA	O
(	O
Table	O
4	O
)	O
.	O

Standard	O
error	O
of	O
the	O
mean	O
expressed	O
as	O
percentage	O
was	O
calculated	O
for	O
the	O
4	O
technical	O
replicates	O
,	O
and	O
was	O
6.7	O
%	O
for	O
the	O
top	O
25	O
genes	O
up	O
-	O
regulated	O
in	O
hESC	O
samples	O
,	O
compared	O
to	O
universal	O
reference	O
RNA	O
.	O

We	O
performed	O
the	O
analysis	O
of	O
microarray	O
data	O
,	O
as	O
described	O
in	O
the	O
Methods	O
,	O
and	O
spot	O
error	O
values	O
were	O
generally	O
in	O
the	O
lower	O
range	O
,	O
indicating	O
high	O
stringency	O
of	O
the	O
signals	O
and	O
low	O
variance	O
.	O

As	O
seen	O
in	O
Table	O
4	O
and	O
Table	O
5	O
,	O
the	O
NeuroStem	O
Chip	O
identified	O
numerous	O
genes	O
associated	O
with	O
stem	O
cells	O
.	O

In	O
particular	O
,	O
homeo	B
box	I
expressed	I
in	I
ES	I
cells	I
1	I
(	O
Hesx1	B
)	O
gene	O
was	O
identified	O
as	O
the	O
most	O
up	O
-	O
regulated	O
in	O
the	O
ES	O
cell	O
preparation	O
,	O
compared	O
to	O
universal	O
reference	O
RNA	O
.	O

Highly	O
expressed	O
in	O
pluripotent	O
ESCs	O
,	O
Hesx1	B
expression	O
is	O
down	O
-	O
regulated	O
upon	O
embryonic	O
stem	O
cell	O
differentiation	O
[	O
35,36	O
]	O
,	O
as	O
also	O
clearly	O
seen	O
in	O
differentiation	O
experiment	O
of	O
our	O
own	O
(	O
Table	O
4	O
)	O
.	O

Similarly	O
,	O
Gremlin	B
1	I
homolog	I
,	I
cysteine	I
knot	I
superfamily	I
gene	I
(	O
Grem1	B
,	O
also	O
known	O
as	O
Cktsf1b1	B
and	O
Dand2	B
)	O
is	O
a	O
recognized	O
factor	O
of	O
cell	O
-	O
fate	O
determination	O
of	O
ESCs	O
[	O
37	O
]	O
.	O

Many	O
more	O
genes	O
highly	O
up	O
-	O
regulated	O
in	O
the	O
hESC	O
sample	O
in	O
comparison	O
with	O
universal	O
reference	O
RNA	O
are	O
associated	O
with	O
stem	O
cells	O
:	O
further	O
examples	O
include	O
Gap	B
junction	I
protein	I
α1	I
(	O
Gja1	B
)	O
and	O
Zic	B
family	I
member	I
3	I
heterotaxy	I
1	I
(	O
Zic3	B
)	O
(	O
Table	O
4	O
)	O
[	O
20	O
]	O
.	O

The	O
expression	O
of	O
fibroblast	B
growth	I
factor	I
receptor	I
2	I
(	O
Fgfr2	B
)	O
is	O
of	O
particular	O
interest	O
.	O

Basic	B
fibroblast	I
growth	I
factor	I
(	O
FGF2	B
,	O
bFGF	B
)	O
supports	O
hESC	O
proliferation	O
and	O
their	O
ability	O
to	O
maintain	O
undifferentiated	O
phenotype	O
when	O
cultured	O
in	O
vitro	O
[	O
38,39	O
]	O
.	O

Moreover	O
,	O
in	O
some	O
hESC	O
lines	O
a	O
very	O
high	O
concentration	O
of	O
FGF2	B
could	O
substitute	O
for	O
the	O
need	O
of	O
feeder	O
cells	O
[	O
40	O
]	O
.	O

At	O
the	O
same	O
time	O
,	O
genes	O
listed	O
in	O
Table	O
4	O
represent	O
the	O
most	O
highly	O
up	O
-	O
regulated	O
entries	O
in	O
a	O
relatively	O
limited	O
group	O
of	O
genes	O
(	O
Figure	O
5C	O
)	O
.	O

Many	O
other	O
genes	O
involved	O
in	O
maintenance	O
of	O
ESC	O
phenotype	O
(	O
i.e.	O
established	O
or	O
candidate	O
markers	O
of	O
stem	O
cells	O
)	O
have	O
lower	O
levels	O
of	O
expression	O
(	O
Table	O
5	O
)	O
.	O

Examples	O
include	O
undifferentiated	B
embryonic	I
cell	I
transcription	I
factor	I
1	I
(	O
Utf1	B
)	O
,	O
DNA	B
methyltransferase	I
3B	I
(	O
Dnmt3b	B
)	O
,	O
developmental	B
pluripotency	I
associated	I
4	I
(	O
Dppa4	B
,	O
a	O
newly	O
established	O
pluripotency	O
marker	O
[	O
41	O
]	O
)	O
and	O
numerous	O
candidate	O
markers	O
of	O
""""	O
stemness	O
""""	O
:	O
e.g.	O
genes	O
for	O
KIAA1573	B
protein	I
,	O
forkhead	B
box	I
O1A	I
(	O
Foxo1a	B
)	O
,	O
high	B
-	I
mobility	I
group	I
box	I
1	I
(	O
Hmgb1	B
)	O
,	O
C	B
-	I
terminal	I
binding	I
protein	I
2	I
(	O
Ctbp2	B
)	O
and	O
left	B
-	I
right	I
determination	I
factor	I
1	I
(	O
Lefty1	B
)	O
,	O
as	O
well	O
as	O
others	O
.	O

For	O
numerous	O
established	O
or	O
candidate	O
markers	O
of	O
stem	O
cells	O
the	O
expression	O
levels	O
were	O
not	O
considerably	O
higher	O
(	O
Log2	O
ratio	O
<	O
1	O
)	O
in	O
the	O
hESC	O
sample	O
compared	O
to	O
the	O
universal	O
reference	O
RNA	O
.	O

For	O
example	O
,	O
the	O
expression	O
of	O
Nanog	B
,	O
DNA	B
(	I
cytosine-5-	I
)	I
-methyltransferase	I
3α	I
(	O
Dnmt3a	B
)	O
,	O
MutS	B
homolog	I
2	I
,	I
colon	I
cancer	I
,	I
nonpolyposis	I
type	I
1	I
(	I
E.	I
coli	I
)	I
(	O
Msh2	B
)	O
,	O
Thy-1	B
cell	I
surface	I
antigen	I
(	O
Thy1	B
)	O
,	O
high	B
-	I
mobility	I
group	I
box	I
2	I
(	O
Hmgb2	B
)	O
,	O
transcription	B
factor	I
3	I
(	O
Tcf3	B
)	O
,	O
Nanos	B
homolog	I
1	I
(	O
Nanos1	B
)	O
,	O
MyoD	B
family	I
inhibitor	I
(	O
Mdfi	B
)	O
,	O
Calumenin	B
(	O
Calu	B
)	O
and	O
soluble	B
thymidine	I
kinase	I
1	I
(	O
Tk1	B
)	O
was	O
detected	O
in	O
hES	O
SA02	O
cells	O
with	O
Log2	O
ratio	O
value	O
<	O
1	O
.	O

Expression	O
levels	O
of	O
those	O
genes	O
range	O
from	O
being	O
inconsiderably	O
higher	O
to	O
nearly	O
equal	O
to	O
that	O
in	O
universal	O
reference	O
RNA	O
sample	O
.	O

We	O
believe	O
that	O
those	O
findings	O
could	O
be	O
explained	O
by	O
cellular	O
composition	O
of	O
human	O
universal	O
reference	O
RNA	O
sample	O
[	O
42	O
]	O
,	O
which	O
includes	O
pooled	O
RNA	O
samples	O
from	O
proliferating	O
cells	O
(	O
e.g.	O
,	O
skin	O
and	O
testis	O
cell	O
lines	O
)	O
.	O

Thus	O
,	O
the	O
relative	O
difference	O
between	O
gene	O
expression	O
of	O
certain	O
markers	O
of	O
stem	O
cells	O
in	O
undifferentiated	O
hESCs	O
and	O
universal	O
reference	O
RNA	O
is	O
naturally	O
decreased	O
.	O

Taken	O
together	O
,	O
the	O
gene	O
expression	O
signature	O
of	O
hES	O
SA02	O
cell	O
line	O
profiled	O
by	O
NeuroStem	O
Chip	O
is	O
indeed	O
characteristic	O
for	O
pluripotent	O
stem	O
cells	O
,	O
providing	O
proof	O
-	O
of	O
-	O
concept	O
.	O

Notably	O
,	O
comparison	O
of	O
expression	O
profiles	O
of	O
undifferentiated	O
hESCs	O
and	O
hESC	O
-	O
derived	O
cells	O
committed	O
toward	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
SDIA	B
for	O
16	O
days	O
have	O
revealed	O
that	O
many	O
of	O
the	O
stem	O
cell	O
marker	O
genes	O
mentioned	O
above	O
were	O
down	O
-	O
regulated	O
in	O
differentiation	O
(	O
Table	O
5	O
)	O
.	O

Expectedly	O
,	O
Hesx1	B
,	O
Grem1	B
,	O
Dnmt3b	B
,	O
Utf1	B
and	O
Nanog	B
could	O
be	O
listed	O
among	O
these	O
.	O

At	O
the	O
same	O
time	O
,	O
numerous	O
other	O
genes	O
,	O
including	O
Pitx2	B
,	O
Dlk1	B
and	O
Msx1	B
were	O
up	O
-	O
regulated	O
in	O
the	O
latter	O
sample	O
(	O
[	O
see	O
Additional	O
file	O
2	O
]	O
,	O
Figure	O
3	O
)	O
.	O

Table	O
1	O
lists	O
24	O
dopaminergic	O
system	O
-	O
related	O
entries	O
(	O
e.g.	O
,	O
Ptx3	B
,	O
Th	B
,	O
Lhx1	B
)	O
with	O
gene	O
expression	O
up	O
-	O
regulated	O
by	O
Day	O
16	O
of	O
hESC	O
differentiation	O
protocol	O
;	O
few	O
more	O
genes	O
have	O
demonstrated	O
less	O
prominent	O
up	O
-	O
regulation	O
(	O
Log2	O
ratio	O
values	O
in	O
the	O
range	O
of	O
0.7	O
/	O
0.97–1.0	O
)	O
.	O

The	O
gene	O
expression	O
profiles	O
generated	O
are	O
therefore	O
consistent	O
with	O
the	O
results	O
of	O
earlier	O
studies	O
utilizing	O
hSC	O
-	O
derived	O
samples	O
with	O
similar	O
characteristics	O
[	O
43,44	O
]	O
.	O

Diversity	O
of	O
NeuroStem	O
Chip	O
entries	O
responsive	O
to	O
hESC	O
commitment	O
toward	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
clearly	O
illustrates	O
the	O
complexity	O
of	O
that	O
pathway	O
.	O

The	O
cell	O
population	O
obtained	O
after	O
16	O
day	O
exposure	O
to	O
SDIA	O
is	O
highly	O
heterogeneous	O
.	O

Only	O
around	O
0.2	O
%	O
of	O
the	O
cells	O
are	O
TH	B
-	O
positive	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

This	O
heterogeneity	O
,	O
with	O
an	O
apparent	O
presence	O
of	O
residual	O
pluripotent	O
cells	O
explains	O
the	O
presence	O
of	O
stem	O
cell	O
marker	O
genes	O
,	O
including	O
homeobox	B
transcription	I
factor	I
Nanog	B
,	O
as	O
revealed	O
by	O
RT	O
-	O
PCR	O
data	O
(	O
Figure	O
3	O
)	O
.	O

It	O
would	O
be	O
therefore	O
impossible	O
to	O
apply	O
the	O
platform	O
to	O
identify	O
novel	O
genes	O
associated	O
with	O
the	O
process	O
of	O
differentiation	O
;	O
for	O
that	O
application	O
,	O
the	O
genome	O
-	O
scale	O
microarray	O
platforms	O
(	O
e.g.	O
,	O
Affymetrix	O
)	O
are	O
clearly	O
superior	O
.	O

Nevertheless	O
,	O
being	O
based	O
upon	O
a	O
moderate	O
assay	O
of	O
pre	O
-	O
selected	O
specific	O
gene	O
targets	O
,	O
the	O
comparative	O
analysis	O
of	O
microarray	O
data	O
derived	O
from	O
undifferentiated	O
and	O
dopaminergic	O
differentiate	O
pathway	O
-	O
committed	O
hESCs	O
provides	O
a	O
valuable	O
cross	O
-	O
cut	O
of	O
complex	O
relationship	O
between	O
factors	O
driving	O
or	O
indicative	O
to	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
[	O
see	O
Additional	O
file	O
2	O
]	O
.	O

RT	O
-	O
PCR	O
analyses	O
have	O
validated	O
the	O
overall	O
reliability	O
of	O
NeuroStem	O
microarray	O
platform	O
:	O
all	O
of	O
the	O
entries	O
detected	O
in	O
the	O
hybridization	O
experiments	O
have	O
demonstrated	O
similar	O
trends	O
when	O
analyzed	O
by	O
RT	O
-	O
PCR	O
means	O
(	O
Figure	O
3	O
)	O
.	O

Those	O
entries	O
include	O
Sox2	B
,	O
En1	B
and	O
Nanog	B
(	O
ratio	O
of	O
differentiated	O
/	O
undifferentiated	O
hESC	O
sample	O
normalized	O
spot	O
intensity	O
<	O
0.75	O
,	O
down	O
-	O
regulated	O
)	O
,	O
Gadph	B
,	O
Aldh1a1	B
,	O
Sdha	B
,	O
Tubb	B
and	O
Nestin	B
(	O
ratio	O
.1.0	O
,	O
unchanged	O
)	O
,	O
Actb	B
,	O
Th	B
,	O
Msx1	B
and	O
Pitx2	B
(	O
ratio	O
>	O
1.25	O
,	O
up	O
-	O
regulated	O
)	O
.	O

Some	O
of	O
the	O
housekeeping	O
genes	O
(	O
Gapdh	B
,	O
Sdha	B
,	O
Tubb	B
,	O
Actb	B
)	O
have	O
somewhat	O
different	O
expression	O
in	O
undifferentiated	O
vs.	O
differentiated	O
cells	O
,	O
consistent	O
with	O
previous	O
reports	O
on	O
certain	O
established	O
housekeeping	O
genes	O
(	O
including	O
Gapdh	B
)	O
being	O
variable	O
in	O
human	O
samples	O
[	O
45	O
]	O
.	O

Importantly	O
,	O
all	O
the	O
observed	O
gene	O
expression	O
trends	O
were	O
similar	O
in	O
both	O
microarray	O
and	O
RT	O
-	O
PCR	O
.	O

Our	O
experiment	O
therefore	O
confirms	O
that	O
the	O
NeuroStem	O
Chip	O
microarray	O
platform	O
can	O
still	O
identify	O
gene	O
expression	O
changes	O
related	O
to	O
early	O
stages	O
of	O
differentiation	O
of	O
hESC	O
into	O
dopaminergic	O
neurons	O
.	O

Recent	O
technological	O
advances	O
have	O
led	O
to	O
DNA	O
microarrays	O
which	O
contain	O
over	O
hundred	O
thousand	O
of	O
spots	O
of	O
DNA	O
material	O
,	O
reaching	O
a	O
truly	O
genomic	O
scale	O
.	O

Highly	O
specialized	O
DNA	O
microarrays	O
of	O
smaller	O
scale	O
(	O
e.g.	O
the	O
NeuroStem	O
Chip	O
)	O
still	O
have	O
an	O
important	O
role	O
in	O
the	O
directed	O
studies	O
in	O
particular	O
fields	O
.	O

Since	O
they	O
are	O
significantly	O
less	O
expensive	O
,	O
compared	O
to	O
many	O
recognized	O
large	O
-	O
scale	O
platforms	O
(	O
e.g.	O
Affymetrix	O
Human	O
Genome	O
platforms	O
)	O
,	O
they	O
have	O
a	O
clear	O
advantage	O
in	O
routine	O
work	O
involving	O
samples	O
from	O
,	O
e.g.	O
,	O
multiple	O
cell	O
culture	O
conditions	O
.	O

While	O
there	O
is	O
a	O
risk	O
that	O
one	O
will	O
miss	O
out	O
on	O
changes	O
in	O
genes	O
previously	O
not	O
believed	O
to	O
be	O
relevant	O
to	O
neural	O
differentiation	O
,	O
the	O
restricted	O
number	O
of	O
genes	O
in	O
the	O
NeuroStem	O
Chip	O
also	O
simplifies	O
analysis	O
and	O
adds	O
power	O
.	O

NeuroStem	O
Chip	O
is	O
comparable	O
to	O
other	O
stem	O
cell	O
-	O
related	O
focused	O
microarray	O
platforms	O
in	O
regards	O
to	O
manufacturing	O
costs	O
and	O
technical	O
simplicity	O
of	O
the	O
recommended	O
hybridization	O
protocols	O
.	O

At	O
the	O
same	O
time	O
,	O
it	O
currently	O
implies	O
an	O
advantage	O
in	O
both	O
the	O
scale	O
and	O
the	O
spectrum	O
of	O
pre	O
-	O
selected	O
,	O
specific	O
gene	O
targets	O
assayed	O
.	O

Some	O
suggested	O
areas	O
of	O
application	O
for	O
NeuroStem	O
microarray	O
platform	O
could	O
be	O
the	O
following	O
:	O
(	O
i	O
)	O
characterization	O
of	O
the	O
expression	O
of	O
established	O
,	O
pre	O
-	O
selected	O
gene	O
targets	O
in	O
human	O
stem	O
cell	O
(	O
hSC	O
)	O
lines	O
,	O
including	O
newly	O
derived	O
ones	O
,	O
(	O
ii	O
)	O
longitudinal	O
quality	O
control	O
for	O
maintained	O
hSC	O
populations	O
,	O
(	O
iii	O
)	O
following	O
gene	O
expression	O
changes	O
during	O
differentiation	O
under	O
defined	O
cell	O
culture	O
conditions	O
,	O
and	O
(	O
iv	O
)	O
confirming	O
the	O
success	O
of	O
differentiation	O
into	O
specific	O
neuronal	O
subtypes	O
.	O

In	O
addition	O
,	O
the	O
NeuroStem	O
Chip	O
can	O
be	O
used	O
to	O
characterize	O
gene	O
changes	O
in	O
intracerebral	O
grafts	O
of	O
human	O
cells	O
,	O
even	O
when	O
they	O
are	O
transplanted	O
into	O
experimental	O
animals	O
.	O

We	O
specifically	O
wish	O
to	O
stress	O
that	O
we	O
are	O
about	O
to	O
make	O
the	O
NeuroStem	O
Chip	O
available	O
at	O
a	O
non	O
-	O
profit	O
cost	O
to	O
the	O
research	O
community	O
.	O

We	O
believe	O
it	O
has	O
the	O
potential	O
to	O
become	O
an	O
important	O
screening	O
tool	O
in	O
the	O
expanding	O
field	O
of	O
hSC	O
studies	O
in	O
application	O
to	O
neurological	O
/	O
neurodegenerative	O
disorders	O
.	O

Human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
culturesUndifferentiated	O
hESCs	O
of	O
SA02	O
(	O
Sahlgrenska	O
2	O
)	O
line	O
(	O
Cellartis	O
AB	O
,	O
Göteborg	O
,	O
Sweden	O
;	O
see	O
NIH	O
Human	O
Embryonic	O
Stem	O
Cell	O
Registry	O
at	O
[	O
46	O
]	O
)	O
were	O
maintained	O
over	O
a	O
monolayer	O
of	O
human	O
""""	O
feeder	O
cells	O
""""	O
(	O
hFCs	O
;	O
human	O
foreskin	O
fibroblasts	O
,	O
ATCC	O
;	O
cell	O
line	O
CCD-1112Sk	O
)	O
.	O

Feeder	O
cells	O
were	O
grown	O
in	O
hFC	O
medium	O
(	O
Iscove	O
's	O
modified	O
Dulbecco	O
's	O
medium	O
(	O
IMDM	O
)	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
FCS	O
(	O
Stem	O
Cell	O
Technologies	O
,	O
USA	O
)	O
and	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
mix	O
)	O
for	O
11	O
passages	O
.	O

One	O
day	O
prior	O
to	O
hESC	O
plating	O
,	O
hFC	O
medium	O
was	O
washed	O
away	O
from	O
the	O
hFCs	O
,	O
the	O
latter	O
were	O
resuspended	O
in	O
a	O
hESC	O
proliferation	O
medium	O
(	O
VitroHES	O
media	O
(	O
Vitrolife	O
AB	O
,	O
Sweden	O
)	O
supplemented	O
with	O
4	O
ng	O
/	O
ml	O
human	B
recombinant	I
basic	I
FGF	I
(	O
hrbFGF	B
,	O
Biosource	O
International	O
,	O
USA	O
)	O
and	O
plated	O
in	O
a	O
central	O
ring	O
of	O
gelatinized	O
in	O
vitro	O
fertilization	O
(	O
IVF	O
)	O
dishes	O
with	O
a	O
cell	O
density	O
of	O
120,000	O
cells	O
/	O
dish	O
.	O

The	O
outer	O
rings	O
of	O
the	O
IVF	O
dishes	O
were	O
filled	O
with	O
Dulbecco	O
's	O
modified	O
Eagle	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
mix	O
.	O

One	O
half	O
of	O
the	O
culture	O
medium	O
was	O
replaced	O
every	O
other	O
day	O
.	O

The	O
cells	O
were	O
maintained	O
at	O
37	O
°	O
C	O
,	O
5	O
%	O
CO2	O
,	O
95	O
%	O
humidity	O
settings	O
.	O

Every	O
6	O
days	O
,	O
fragments	O
of	O
the	O
hESC	O
colonies	O
(	O
around	O
10–14	O
colonies	O
per	O
dish	O
,	O
measuring	O
around	O
0.015	O
×	O
0.015	O
mm	O
)	O
that	O
had	O
an	O
unaltered	O
morphology	O
(	O
indicating	O
lack	O
of	O
spontaneous	O
differentiation	O
)	O
were	O
mechanically	O
cut	O
from	O
dishes	O
using	O
stem	O
cell	O
knives	O
/	O
transfer	O
pipettes	O
(	O
SweMed	O
Lab	O
International	O
AB	O
,	O
Sweden	O
)	O
and	O
then	O
plated	O
on	O
fresh	O
hFCs	O
.	O

Commitment	O
of	O
hESCs	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathwayCo	O
-	O
culturing	O
with	O
the	O
PA6	O
stromal	O
cell	O
line	O
(	O
MC3T3-G2	O
/	O
Pa6	O
,	O
from	O
RIKEN	O
Cell	O
Bank	O
Japan	O
(	O
RCB	O
1127	O
)	O
,	O
derived	O
from	O
newborn	O
mouse	O
calvaria	O
rapidly	O
generates	O
high	O
numbers	O
of	O
DA	O
neurons	O
from	O
mouse	O
and	O
monkey	O
ESCs	O
by	O
an	O
unknown	O
mechanism	O
named	O
stromal	B
-	I
derived	I
inducing	I
activity	I
(	O
SDIA	B
;	O
[	O
28,29	O
]	O
)	O
.	O

For	O
differentiation	O
experiments	O
,	O
PA6	O
cells	O
were	O
plated	O
on	O
gelatine	O
-	O
coated	O
T25	O
flasks	O
at	O
16	O
×	O
103	O
cells	O
/	O
cm2	O
(	O
400,000	O
cells	O
/	O
flask	O
)	O
density	O
2	O
days	O
prior	O
to	O
introducing	O
hESCs	O
into	O
the	O
co	O
-	O
culture	O
and	O
cultured	O
at	O
PA6	O
culturing	O
media	O
(	O
containing	O
minimum	O
essential	O
medium	O
alpha	O
(	O
α	O
-	O
MEM	O
)	O
supplemented	O
with	O
10	O
%	O
FCS	O
and	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
)	O
.	O

Alternatively	O
,	O
PA6	O
cells	O
were	O
plated	O
over	O
Type	B
I	I
collagen	I
-	O
coated	O
glass	O
cover	O
-	O
slips	O
placed	O
in	O
wells	O
of	O
4-well	O
-	O
plates	O
(	O
50,000	O
cells	O
/	O
well	O
,	O
for	O
immunocytochemical	O
(	O
ICC	O
)	O
analysis	O
)	O
.	O

Three	O
hours	O
prior	O
to	O
initiation	O
of	O
co	O
-	O
culture	O
,	O
PA6	O
cells	O
were	O
rinsed	O
3	O
times	O
with	O
PBS	O
and	O
media	O
was	O
replaced	O
with	O
co	O
-	O
culture	O
media	O
(	O
Glasgow	O
's	O
modified	O
Eagle	O
's	O
media	O
(	O
G	O
-	O
MEM	O
)	O
supplemented	O
with	O
8	O
%	O
knock	O
-	O
out	O
serum	O
replacement	O
(	O
KSR	O
)	O
,	O
2	O
mM	O
glutamine	O
,	O
0.1	O
mM	O
non	O
-	O
essential	O
amino	O
-	O
acids	O
(	O
NEAA	O
)	O
,	O
1	O
mM	O
pyruvate	O
,	O
0.1	O
mM	O
β	O
-	O
mercaptoethanol	O
(	O
βME	O
)	O
and	O
4	O
ng	O
/	O
μl	O
bFGF	B
)	O
.	O

Fragments	O
of	O
hESC	O
colonies	O
(	O
80–90	O
per	O
flask	O
;	O
4–5	O
per	O
well	O
of	O
4-well	O
-	O
plate	O
)	O
presenting	O
undifferentiated	O
morphology	O
were	O
manually	O
passaged	O
onto	O
the	O
confluent	O
PA6	O
monolayer	O
and	O
cell	O
co	O
-	O
cultures	O
were	O
maintained	O
at	O
37	O
°	O
C	O
,	O
5	O
%	O
CO2	O
,	O
95	O
%	O
humidity	O
settings	O
.	O

One	O
half	O
of	O
the	O
co	O
-	O
culture	O
medium	O
was	O
replaced	O
every	O
other	O
day	O
for	O
first	O
10	O
days	O
,	O
and	O
daily	O
onwards	O
.	O

Characterization	O
of	O
hESCs	O
and	O
hESC	O
-	O
derived	O
cells	O
by	O
immunocytochemistry	O
(	O
ICC	O
)	O
and	O
RT	O
-	O
PCRIVF	O
dishes	O
with	O
hESCs	O
grown	O
atop	O
hFCs	O
and	O
4-well	O
plate	O
dishes	O
with	O
hESCs	O
growing	O
atop	O
PA6	O
cells	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
for	O
15	O
minutes	O
at	O
the	O
day	O
of	O
passage	O
/	O
harvest	O
(	O
Day	O
6	O
of	O
hESC	O
/	O
hFC	O
co	O
-	O
culturing	O
)	O
and	O
Day	O
16	O
of	O
co	O
-	O
culturing	O
with	O
PA6	O
cells	O
,	O
respectively	O
.	O

Cells	O
were	O
pre	O
-	O
incubated	O
with	O
blocking	O
solution	O
containing	O
PBS	O
,	O
0.5	O
%	O
Triton	O
X-100	O
and	O
5	O
%	O
of	O
donkey	O
serum	O
.	O

They	O
were	O
then	O
incubated	O
with	O
primary	O
antibodies	O
in	O
blocking	O
solution	O
overnight	O
at	O
room	O
temperature	O
.	O

After	O
three	O
washes	O
with	O
PBS	O
,	O
cells	O
were	O
incubated	O
with	O
the	O
donkey	B
anti	I
-	I
rabbit	I
IgG	I
conjugated	O
with	O
FITC	O
or	O
anti	O
-	O
mouse	O
Cy3	O
(	O
1:200	O
,	O
Jackson	O
ImmunoResearch	O
Laboratories	O
)	O
.	O

Cells	O
were	O
then	O
washed	O
once	O
with	O
PBS	O
,	O
incubated	O
with	O
1:1000	O
DAPI	O
in	O
PBS	O
for	O
10	O
minutes	O
,	O
followed	O
by	O
another	O
wash	O
with	O
PBS	O
.	O

Coverslips	O
were	O
mounted	O
onto	O
glass	O
slides	O
with	O
PVA	O
mounting	O
medium	O
containing	O
anti	O
-	O
fading	O
reagent	O
DABCO	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
:	O
mouse	B
anti	I
-	I
Oct3	I
/	I
4	I
(	O
1:500	O
,	O
Santa	O
Cruz	O
Biotechnology	O
Inc.	O
)	O
;	O
rabbit	B
anti	I
-	I
Ki67	I
(	O
1:200	O
,	O
Novocastra	O
Ltd.	O
)	O
;	O
rabbit	B
anti	I
-	I
TH	I
(	O
1:500	O
,	O
Chemicon	O
)	O
.	O

Immunostained	O
cell	O
cultures	O
were	O
visualized	O
using	O
a	O
Zeiss	O
fluorescent	O
microscope	O
attached	O
to	O
a	O
Nikon	O
digital	O
camera	O
.	O

Using	O
RT	O
-	O
PCR	O
,	O
all	O
RNA	O
samples	O
used	O
in	O
this	O
study	O
were	O
tested	O
negative	O
for	O
the	O
presence	O
of	O
gDNA	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
intron	O
-	O
spanning	O
primers	O
for	O
RT	O
-	O
PCR	O
were	O
selected	O
from	O
published	O
works	O
or	O
designed	O
using	O
Oligo	O
4.0	O
software	O
(	O
Molecular	O
Biology	O
Insight	O
)	O
or	O
Clone	O
Manager	O
Suite	O
7.1	O
(	O
Sci	O
Ed	O
Software	O
,	O
NC	O
,	O
USA	O
)	O
and	O
ordered	O
from	O
TAG	O
Copenhagen	O
A	O
/	O
S	O
,	O
Denmark	O
,	O
as	O
the	O
following	O
:	O
Sox2	B
,	O
SRY	B
-	I
box	I
2	I
:	O
5'-TAC	O
CTC	O
TTC	O
CTC	O
CC	O
CTC	O
CA-3	O
'	O
,	O
5'-ACT	O
CTC	O
CTC	O
TTT	O
TGC	O
ACC	O
CC-3	O
'	O
;	O
En1	B
,	O
Engrailed	B
1	I
:	O
5'-AAG	O
GGA	O
CGA	O
AAC	O
TGC	O
GAA	O
CTC	O
C-3	O
'	O
,	O
5'-GAC	O
ACG	O
AAA	O
GGA	O
AAC	O
ACA	O
CAC	O
TCT	O
CG-3	O
'	O
[	O
47	O
]	O
;	O
Nanog	B
:	O
5'-TGC	O
TTA	O
TTC	O
AGG	O
ACA	O
GCC	O
T-3	O
'	O
,	O
5'-TCT	O
GGT	O
CTT	O
CTG	O
TTT	O
CTT	O
GAC	O
T-3	O
'	O
[	O
48	O
]	O
;	O
Gapdh	B
,	O
glyceraldehydes-3-phosphate	B
dehydrogenase	I
:	O
5'-GGA	O
AGG	O
TGA	O
AGG	O
TCG	O
GAG	O
TCA	O
A-3	O
'	O
,	O
5'-GAT	O
CTC	O
GCT	O
CCT	O
GGA	O
AGA	O
TGG	O
T-3	O
'	O
;	O
Aldh1A1	B
,	O
aldehyde	B
dehydrogenase	I
1	I
family	I
,	I
member	I
A1	I
:	O
5'-GGG	O
CAG	O
CCA	O
TTT	O
CTT	O
CTC	O
AC-3	O
'	O
,	O
5'-CTT	O
CTT	O
AGC	O
CCG	O
CTC	O
AAC	O
AC-3	O
'	O
[	O
49	O
]	O
;	O
Sdha	B
,	O
succinate	B
dehydrogenase	I
:	O
5'-TGG	O
GAA	O
CAA	O
GAG	O
GGC	O
ATC	O
TG-3	O
'	O
,	O
5'-CCA	O
CCA	O
CTG	O
CAT	O
CAA	O
ATT	O
CAT	O
G-3	O
'	O
[	O
50	O
]	O
;	O
Tubb	B
,	O
β	B
-	I
tubulin	I
:	O
5'-CTC	O
ACA	O
AGT	O
ACG	O
TGC	O
CTC	O
GAG-3	O
'	O
,	O
5'-GCA	O
CGA	O
CGC	O
TGA	O
AGG	O
TGT	O
TCA-3	O
'	O
;	O
Nestin	B
:	O
5'-AGA	O
GGG	O
GAA	O
TTC	O
CTG	O
CT	O
GAG-3	O
'	O
,	O
5'-CTG	O
AGG	O
ACC	O
AGG	O
ACT	O
CTC	O
TA-3	O
'	O
[	O
47	O
]	O
;	O
Actb	B
,	O
β	B
-	I
actin	I
:	O
5'-CAT	O
CGA	O
GCA	O
CGG	O
CAT	O
CGT	O
CA-3	O
'	O
,	O
5'-TAG	O
CAC	O
AGC	O
CTG	O
GAT	O
AGC	O
AAC-3	O
'	O
[	O
51	O
]	O
;	O
Th	B
,	O
Tyrosine	B
hydroxylase	I
:	O
5'-CGA	O
GCT	O
GTG	O
AAG	O
GTG	O
TTT	O
G-3	O
'	O
,	O
5'-TTG	O
GTG	O
ACC	O
AGG	O
TGA	O
TGA	O
C-3	O
'	O
;	O
Msx1	B
,	O
homolog	B
of	I
Drosophila	I
muscle	I
segment	I
homolog	I
1	I
:	O
5'-CTC	O
AAG	O
CTG	O
CCA	O
GAA	O
GAT	O
GC-3	O
'	O
,	O
5'-TCC	O
AGC	O
TCT	O
GCC	O
TCT	O
TGT	O
AG-3	O
'	O
;	O
Pitx2	B
,	O
paired	B
-	I
like	I
homeodomain	I
transcription	I
factor	I
2	I
:	O
5'-ACC	O
TTA	O
CGG	O
AAG	O
CCC	O
GAG	O
TC-3	O
'	O
,	O
5'-TGG	O
ATA	O
GGG	O
AGG	O
CGG	O
ATG	O
TA-3	O
'	O
[	O
49	O
]	O
.	O

cDNA	O
was	O
synthesized	O
from	O
1	O
mg	O
of	O
total	O
RNA	O
using	O
SuperScript	O
II	O
(	O
Invitrogen	O
)	O
,	O
and	O
RT	O
-	O
PCR	O
amplifications	O
were	O
performed	O
using	O
the	O
MiniOpticon	O
system	O
(	O
Bio	O
-	O
Rad	O
)	O
with	O
REDTaq	O
Polymerase	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
essentially	O
as	O
described	O
by	O
the	O
manufacturer	O
.	O

Following	O
initial	O
denaturation	O
for	O
5	O
min	O
at	O
95	O
°	O
C	O
,	O
DNA	O
amplifications	O
were	O
performed	O
for	O
35	O
(	O
En1	B
,	O
Nanog	B
,	O
Aldh1a1	B
)	O
,	O
33	O
(	O
Sox2	B
,	O
Nestin	B
,	O
Th	B
,	O
Msx1	B
)	O
,	O
32	O
(	O
Tubb	B
,	O
Pitx2	B
)	O
,	O
27	O
(	O
Sdha	B
)	O
,	O
25	O
(	O
Actb	B
)	O
or	O
22	O
(	O
Gapdh	B
)	O
cycles	O
of	O
1	O
min	O
at	O
95	O
°	O
C	O
,	O
1	O
min	O
at	O
55	O
°	O
C	O
(	O
En1	B
,	O
Pitx2	B
)	O
,	O
57	O
°	O
C	O
(	O
Sox2	B
,	O
Nanog	B
,	O
Sdha	B
,	O
Nestin	B
)	O
,	O
58	O
°	O
C	O
(	O
Tubb	B
)	O
,	O
58.5	O
°	O
C	O
(	O
Aldh1a1	B
,	O
Th	B
)	O
or	O
59	O
°	O
C	O
(	O
Gapdh	B
,	O
Actb	B
,	O
Msx1	B
)	O
,	O
and	O
1	O
min	O
at	O
72	O
°	O
C	O
.	O

The	O
final	O
extension	O
was	O
5	O
min	O
at	O
72	O
°	O
C	O
.	O

Twenty	O
μl	O
volumes	O
of	O
RT	O
-	O
PCR	O
products	O
were	O
analyzed	O
by	O
electrophoresis	O
at	O
1	O
%	O
agarose	O
gels	O
and	O
visualized	O
by	O
ethidium	O
bromide	O
staining	O
.	O

RNA	O
purification	O
and	O
fluorescent	O
dye	O
incorporationFor	O
RNA	O
purification	O
of	O
undifferentiated	O
hESCs	O
,	O
the	O
latter	O
were	O
mechanically	O
separated	O
from	O
hFCs	O
,	O
collected	O
in	O
a	O
500	O
μl	O
volume	O
of	O
VitroHES	O
media	O
,	O
rinsed	O
in	O
PBS	O
buffer	O
and	O
spun	O
down	O
at	O
300	O
rcf	O
for	O
5	O
min	O
.	O

hESC	O
-	O
derived	O
cells	O
grown	O
atop	O
PA6	O
cells	O
were	O
harvested	O
using	O
a	O
papain	B
dissociation	O
kit	O
(	O
Worthington	O
Biochemical	O
Corporation	O
)	O
,	O
rinsed	O
in	O
PBS	O
buffer	O
and	O
spun	O
down	O
as	O
described	O
above	O
.	O

The	O
resulting	O
cell	O
pellets	O
were	O
resuspended	O
in	O
RLT	O
buffer	O
(	O
Qiagen	O
,	O
USA	O
)	O
,	O
passed	O
through	O
the	O
shredder	O
column	O
(	O
Qiagen	O
)	O
and	O
stored	O
at	O
-80	O
°	O
C	O
until	O
the	O
RNA	O
sample	O
was	O
purified	O
following	O
the	O
RNeasy	O
Micro	O
Kit	O
(	O
Qiagen	O
)	O
protocol	O
(	O
without	O
carrier	O
RNA	O
)	O
;	O
with	O
DNase	B
I	I
(	O
Quiagen	O
)	O
treatment	O
incorporated	O
to	O
the	O
latter	O
.	O

RNA	O
integrity	O
was	O
tested	O
using	O
both	O
ND-1000	O
specrophotometer	O
(	O
NanoDrop	O
,	O
USA	O
)	O
and	O
RNA	O
Nano	O
LabChip	O
/	O
2100	O
Bioanalyzer	O
system	O
(	O
Agilent	O
Technologies	O
,	O
USA	O
)	O
.Fluorescent	O
label	O
(	O
24	O
nmol	O
of	O
the	O
Cyanine	O
3-CTP	O
(	O
Cy3	O
)	O
;	O
PerkinElmer	O
,	O
USA	O
)	O
was	O
incorporated	O
to	O
350–500	O
ng	O
of	O
total	O
RNA	O
amplified	O
using	O
Low	O
RNA	O
Input	O
Fluorescent	O
Linear	O
Amplification	O
Kit	O
(	O
Agilent	O
Technologies	O
)	O
,	O
generally	O
following	O
the	O
kit	O
manufacturer	O
's	O
protocol	O
.	O

Similarly	O
,	O
24	O
nmols	O
of	O
the	O
Cyanine	O
5-CTP	O
(	O
Cy5	O
;	O
PerkinElmer	O
)	O
fluorescent	O
label	O
were	O
incorporated	O
to	O
400	O
ng	O
sample	O
of	O
Human	O
Universal	O
Reference	O
RNA	O
(	O
Stratagene	O
,	O
USA	O
)	O
;	O
in	O
addition	O
,	O
dye	O
-	O
swap	O
replicate	O
amplification	O
were	O
performed	O
.	O

Amplified	O
fluorescent	O
cRNA	O
samples	O
were	O
purified	O
using	O
RNeasy	O
mini	O
-	O
columns	O
(	O
Quiagen	O
)	O
,	O
and	O
fluorescence	O
of	O
the	O
eluted	O
products	O
was	O
measured	O
using	O
ND-1000	O
specrophotometer	O
(	O
NanoDrop	O
)	O
.	O

Microarray	O
technologyLong	O
oligonucleotide	O
probes	O
(	O
69–71	O
nucleotides	O
)	O
matching	O
gene	O
targets	O
of	O
interest	O
were	O
selected	O
from	O
Operon	O
V2	O
and	O
V3	O
human	O
AROS	O
sets	O
(	O
Operon	O
Biotechnologies	O
Inc.	O
,	O
USA	O
)	O
.	O

Arrays	O
were	O
produced	O
by	O
the	O
SweGene	O
DNA	O
Microarray	O
Resource	O
Centre	O
,	O
Department	O
of	O
Oncology	O
at	O
Lund	O
University	O
(	O
Sweden	O
)	O
using	O
a	O
MicroGrid	O
II	O
600R	O
arrayer	O
fitted	O
with	O
MicroSpot	O
10	O
K	O
pins	O
(	O
Harvard	O
BioRobotics	O
,	O
USA	O
)	O
.	O

Printing	O
was	O
performed	O
in	O
a	O
temperature-	O
(	O
18–20	O
°	O
C	O
)	O
and	O
humidity-	O
(	O
44–49	O
%	O
RH	O
)	O
controlled	O
area	O
on	O
Corning	O
UltraGAPS	O
aminosilane	O
slides	O
(	O
Corning	O
Inc.	O
,	O
USA	O
)	O
with	O
140	O
μm	O
spot	O
-	O
to	O
-	O
spot	O
centerdistance	O
and	O
90–110	O
μm	O
average	O
spot	O
size	O
.	O

Following	O
printing	O
,	O
arrays	O
were	O
dried	O
for	O
48	O
hours	O
andstored	O
in	O
a	O
dessicator	O
until	O
used	O
.	O

Microarray	O
slides	O
were	O
UV	O
-	O
cross	O
-	O
linked	O
(	O
800	O
mJ	O
/	O
cm2	O
)	O
,	O
pre	O
-	O
hybridizedwith	O
fluorescently	O
labeled	O
samples	O
using	O
the	O
Pronto	O
!	O

Universal	O
Microarray	O
Hybridization	O
Kit	O
(	O
Corning	O
)	O
and	O
subsequently	O
hybridized	O
with	O
test	O
(	O
Cy3-labeled	O
)	O
/	O
reference	O
(	O
Cy5-labeled	O
)	O
RNA	O
samples	O
(	O
or	O
in	O
reverse	O
dye	O
-	O
labeling	O
order	O
)	O
at	O
42	O
°	O
C	O
for	O
17	O
h	O
using	O
a	O
MAUI	O
hybridization	O
station	O
(	O
BioMicro	O
Systems	O
Inc.	O
,	O
USA	O
)	O
and	O
the	O
Pronto	O
!	O

Universal	O
Microarray	O
Hybridization	O
Kit	O
,	O
generally	O
following	O
manufacturer	O
's	O
instructions	O
,	O
with	O
several	O
minor	O
adaptations	O
[	O
31	O
]	O
.	O

Data	O
acquisition	O
and	O
statistical	O
analysisImmediately	O
following	O
the	O
washing	O
steps	O
,	O
the	O
fluorescence	O
intensities	O
were	O
measured	O
using	O
a	O
confocal	O
laser	O
scanner	O
(	O
G2505B	O
,	O
Agilent	O
Technologies	O
)	O
.	O

After	O
image	O
formatting	O
by	O
Tiff	O
Image	O
Channel	O
Splitter	O
Utility	O
(	O
Agilent	O
Technologies	O
)	O
and	O
grid	O
annotation	O
,	O
a	O
complete	O
set	O
of	O
spots	O
was	O
visually	O
inspected	O
for	O
each	O
slide	O
.	O

Using	O
GenePix	O
Pro	O
(	O
Molecular	O
Devices	O
Corp.	O
USA	O
)	O
flags	O
for	O
artifactual	O
spots	O
were	O
annotated	O
for	O
each	O
spot	O
.	O

Median	O
pixel	O
intensity	O
minus	O
the	O
median	O
local	O
background	O
for	O
both	O
dyes	O
was	O
used	O
to	O
obtain	O
a	O
test	O
over	O
reference	O
intensity	O
ratio	O
.	O

Data	O
normalization	O
was	O
performed	O
per	O
array	O
subgrid	O
using	O
LOWESS	O
curve	O
fitting	O
with	O
a	O
smoothing	O
factor	O
of	O
0.33	O
[	O
52,53	O
]	O
.	O

All	O
normalizations	O
,	O
filtering	O
,	O
merging	O
of	O
technical	O
replicates	O
and	O
analyses	O
were	O
performed	O
in	O
the	O
BioArray	O
Software	O
Environment	O
database	O
[	O
32	O
]	O
.	O

To	O
visualize	O
sample	O
-	O
dependent	O
variation	O
of	O
spot	O
intensities	O
,	O
data	O
was	O
uploaded	O
to	O
the	O
TIGR	O
MultiExperiment	O
Viewer	O
(	O
MEV	O
;	O
[	O
34	O
]	O
)	O
.	O

